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DYSLIPIDEMIA IN TREATMENT NAÏVE HIV 
 
INTRODUCTION 
ABSTRACT 
The natural history of human immunodeficiency virus (HIV) infection 
changes with the use of highly active antiretroviral therapy (HAART) through 
reduction in risks of death associated with the condition and improvement of the 
quality of life of people living with the infection. Abnormalities of lipid 
metabolism are common in HIV infected patients and tend to be accentuated in 
those receiving highly active antiretroviral therapy (HAART). The study was 
conducted to describe the pattern of lipid profile among treatment naïve-HIV 
positive patients.  
Aims and objectives: 
 To study the derangement of lipid profile in treatment naïve HIV  
Methods: 
 Data were collected from 100 normotensive, non-diabetic and non-obese 
treatment and 100 age and sex matched healthy controls. The study was carried out 
at ART center in Govt.Rajaji Hospital, Madurai from December 2013 to July 2014. 
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Results: 
 The study observed a significant increased level of triglycerides and low 
density lipoprotein cholesterol and a significant decreased level of total cholesterol 
and high density lipoprotein cholesterol. 
Conclusion: 
 HIV-I replication alone without any influence of human genetic factors and 
antiviral drugs induces changes in serum lipid profile which could be used to 
determine HIV-infected persons with high risk of Myocardial infarction before 
enrollment for HAART.   
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REVIEW OF LITERATURE 
AIDS has its root in Africa, because some Simian immunodeficiency viruses 
are closely associated with HIV-1 & HIV-2, a relative counterpart of virus in an 
African Monkey Sooty-mangabey.  So, HIV-2’s relation to the Sooty-Mangabey is 
the reliable evidence for animal to man transfers of HIV. 
It’s very difficult to exactly pin down the likely source of HIV-1. The closest 
Simian virus to HIV-1 discovered till date has been found in some Chimpanzees.  
Even though, it is very difficult to prove that HIV has its origin from Primates, it 
has been known to infect humans. 
In humans, an adult male, who lived in the Democratic Republic of Congo, 
was the very first evidence for HIV infection. 
In 1959, researchers have gained success in separating the virus from a 
Plasma sample, which was taken from the man. They strongly believed that the 
origin of this strain may be from 1940s or 1950s and it should have spread among 
humans, a decade or much earlier. 
In 1981, cases of very rare opportunistic infections, Pneumocystis causing 
pneumonia and an uncommon skin tumor of endothelial cell origin Kaposi 
Sarcoma were reported in New York and California in epidemic proportions 
among previously healthy young homosexual and bisexual men, who were not 
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known to be predisposed previously to these diseases. With the rapidly increasing 
report of such cases, it was soon recognized that other life threatening infections & 
neoplastic diseases were also observed and found to be attributed to an 
unexplained defect in cell mediated immunity common to each of these patients. 
In early 1982, the group of disease entities was named the Acquired Immuno 
Deficiency Syndrome. 
In June 1982, a group of cases among gay men in Southern California has 
suggested that sexually transmitted infections agent may be the etiological agent 
and initially, the syndrome was named ―GRID‖ (gay related immune deficiency).  
At the same time, the disease was reported among hemopiliacs & in female 
sexual contacts of infected men suggesting transmission through sexual route and 
blood also. 
By August 1982, the gay related immune deficiency was emerged to new 
CDC – coined term AIDS (Acquired Immuno Deficiency Syndrome) and the CDC 
has revised this term to add various syndromes acknowledged as manifestations of 
advanced HIV disease in September 1982. 
 In May 1983, Luc montagmier and his colleagues (Paster institute - Paris) 
isolated a retrovirus from AIDS patient presented with generalised 
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lymphadenopathy and named it as Lymphadenopathy Associated Virus (LAV) 
which was similar but different from HTLV-1 & HTLV-2. 
 In May 1984, Robert C Gallo and colleagues (National Institute of Health - 
Bethesdo) isolated a retrovirus from AIDS patient, similar to HTLV and called it 
HTLV-III 
 Cloning and molecular characteristics of genetic materials proved that both 
the viruses were similar and consistent isolation from patients of different origin, 
with higher degree of tropism of CD4 lymphocyte and isolation of similar Simian 
virus causing AIDS in Macaques proved that HTLV-III/LAV was the etiological 
agent of AIDS. 
 Screening tests for HIV in blood donors in industrialized countries was 
started in 1984.  
 In 1986, centers for disease control provided working definition of AIDS and 
HTLV-III/LAV were renamed as HIV in Viral Taxonomy by International 
committee. 
Antiretroviral therapy: 
 In the history of medicine, the advancement of antiretroviral therapy had 
been one of the most impressive progression. 
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 The years between 1987-1990 brought in trust and some earliest 
advancements using monotherapy but when the results of the study had arrived, not 
only patients but also researchers had immersed in to a depression which endured 
for many years. In 1985, Zidovudine was tested among humans and in March 
1987, it was introduced as a treatment with great expectations. Initially it didn’t 
appear to be most effective. 
 Then the preliminary results of the European – Australian DELTA study and 
the American ACTG 175 study gained attention. It became apparent that 
combination therapy with two nucleoside analogs was more effective than single 
agent therapy. Indeed the differences made on the clinical endpoints (AIDS, death) 
were highly significant. Both studies showed that it was potentially great important 
to immediately start treatment with two nucleoside analogs as opposed to using the 
drugs sequentially. 
Epidemiology:  
 The prevalence of HIV/AIDS varies to a great extent from region to region, 
from nation to nation and from continent to continent. The joint UN program on 
HIV/AIDS provides considerably the best and broad overview. The yearly AIDS 
epidemic update of UNAIDS describes the recent advancements in the global 
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HIV/AIDS epidemic with maps and regional sum-ups. It inquires recent trends in 
the epidemic’s evolution and renders the latest estimates of the epidemic’s scope. 
Global Trends: 
 From the beginning of the epidemic, about 75 million people have been 
infected with HIV virus and over 36 million people died of HIV whereas in 2012 
alone, about 1.6 million people across the world have died due to AIDS related 
disorders. At the end of 2012, 35.3 million (32.2 – 38.8 million) people were living 
with HIV globally. About 0.8% of adults aged between 15-49 years are living with 
HIV worldwide, even if the burden of the epidemic pursues to vary substantially 
between nations and regions. The most severely affected region with nearly 1 in 
every 20 people living with HIV is Sub – Saharan Africa, which accounts for 71% 
among people living with HIV worldwide. 
 In low and middle income countries, about 9.7 million people infected by 
HIV had access to antiretroviral therapy in 2012, which indicates about 61% of 
people were qualified for medication under 2010 WHO recommendation and 
around 34% of people qualified under 2013 WHO guidelines. 
India: 
 By 2012, the estimated number of HIV infected people was 0.3% of total 
population aged between 15-49 years with HIV related deaths of 11 per 10,00,00 
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population. ART coverage among people with HIV infection eligible for ART is 
44-58%. 
 Districts, which has HIV prevalence more than 3% in Antenatal clinic 
attendees were Prakasam, Mahbubnagar, Nizamabad and West Godavari in Andhra 
Pradesh, Hassan and Belgaum in Karnataka, Chandrapur and Sanglii in 
Maharashtra, Wehrul in Manipur, Ganjam in Orissa, Tuensang in Nagaland, 
Ganganagar in Rajasthan, Salem and Namakkal in Tamil Nadu. Districts which 
have HIV prevalence more than 15% in sexually transmitted disease clinic 
attendees were Khammam, Prakasam, Krishna, Vishakapatnam, Hyderabad, 
Warangal and Chitoor in Andhra Pradesh, Sangli, Mumbai and Nagpur in 
Maharashtra, Bellary in Karnataka, Tirunelveli and Madurai in Tamil Nadu, 
Ahmedabad in Gujarat. 
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Virology: 
HIV 
Taxonomy – Human Immunodeficiency Virus 
Family – Retrovirida 
Subfamily – Lentivirinae 
Genus – Lentivirus 
 
Fig.1: Structure of HIV 
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 Subtype C of M group of HIV-I is the most common form prevalent 
worldwide and in India. Subtypes of HIV seen in India are given below: 
 HIV – I virus 98% 
 HIV – II  virus <2% 
 Subtype of HIV –I virus 
o 95% Class C 
o 3% Class A 
o Rest Class B  
Morphology: 
 HIV, like other retroviruses has an icosahedral structure with multiple 
external spikes. The virus has a bilipid layer of envelope within which host 
proteins like major histocompatability complex antigens are incorporated and 
spikes are formed by glycoprotein 120(gp-120) which is linked non-covalently to 
transmembrane glycoprotein 41 (gp-41). Inside the envelope is a cone shaped 
capsid made of p24 viral protein, which contains 2 single stranded RNA. 
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HIV Gene Gene product Function 
gag p17 Matrix protein 
 p24 Capsid protein 
 p7 Nucleocapsid promotes 
RNA dimerization and 
encapsidation 
 p6 Not known, role in 
budding of virus 
env gp160 Precursor of gp120 and 
gp41 
 gp120 Surface envelope 
glycoprotein for binding 
to CD4 molecule 
 gp41 Transmembrane 
glycoprotein results in 
membrane fusion of virus 
envelope with CD4 
lymphocyte 
pol Protease Cleaves gag and pol gene 
products 
 Reverse Transcriptase Catalyze reverse 
transcription of HIV RNA 
to double stranded DNA 
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HIV Gene Gene product Function 
 Integrase Integrates viral DNA in to 
host cell chromosome 
Tat Tat Enhances transcription of 
viral RNA 
Rev Rev Cytoplasmic transport of 
unspliced RNA 
Vpu Vpu Promotes selective 
degradation of CD4 also 
facilitates virion release 
from host cell 
Vif Vif Stabilizes the virion upon 
entry in to host cell 
Vpr Vpr Induces arrest of host cell 
in G2 phase 
Nef Nef Down regulates CD4 and 
major histocompatibility 
complex expression 
 
Table 1: HIV Gene, Proteins and Their Function. 
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Transmission: 
 
Fig. 2: Various Modes of HIV Transmission 
Sexual Transmission: 
 The global prevalence of AIDS epidemic is mainly due to the sexual 
transmission of HIV-I and the degree by which it can be reduced determines the 
future of AIDS expansion globally. Among heterosexuals, sexual transmission is 
the most predominant way of spread of HIV. HIV is sexually transmitted by penile 
vaginal intercourse and penile anal intercourse and sometimes through fellution. 
Vaginal intercourse could transmit the disease to either male or female but the risk 
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is more to female partner. Meta-analysis from various studies regarding HIV 
transmission found that use of barrier methods like condom has an efficiency of 
69% and use of Zidovudine resulted in reduced amount of retrovirus in semen. 
IV drug use related HIV infection: 
 HIV transmission in injection drug abusers happens mostly through 
contamination of injection paraphernalia by HIV infected blood, and this is re-used 
by an uninfected drug users but this mode of transmission is greatly reduced after 
the introduction of disposable syringes. However sharing the same injection is a 
usual practice with injection drug abusers all over the world. Sharing of syringes, 
needles, and some other injection equipment is the foremost risk factor.  
Vertical transmission: 
 HIV infections in children are mainly due to Perinatal transmission from 
infected mother. 
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Fig. 3: HIV Infections 
Transmission by other routes: 
 Blood products derived from an infected person and processed in to a blood 
component transmit HIV. i.e., fresh frozen plasma, whole blood packed red cells, 
platelets and cryoprecipitate. 
HIV disease: Pathogenesis: 
 Chronicity is the characteristic of HIV infection and has several targets 
including CD4+Tcells dendritic cells and macrophages. 
 HIV mostly enters the host through the genital mucosa. The viral envelope 
protein, binds to the CD4 molecule. Interstitial dendritic cells found in 
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cervicovaginal epithelium as well as adenoidal and tonsillar tissue, the usual first 
target cells in infections acquired through genito-oral sex. 
 Viral entry in to these cells is facilitated by different co-receptors. The virus 
enters macrophage, when gp-1 interacts with the chemokine receptor CCR5 as well 
as CD4. Macrophage tropic viruses are designated as R5 in comparison to T cell 
tropic viruses, which are called X4, based upon the CXCR4 receptor on these cells. 
Patients are relatively resistant to R5 infection if they are homozygous for a 
deletion in CCR5. 
 HIV infected cells fuse with CD4 + T cells, leading to spread of the virus. 
HIV is detectable in regional lymph nodes within two days of mucosal exposure 
and within 5 days in plasma. 
 
Fig. 4: Replication of HIV 
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          Once virus enters the blood, there is widespread dissemination to organs 
such as spleen, lymph node as well as brain. Viremia occurs between 5 to 30 days 
after experimental intra-vaginal HIV exposure. 
 This initial viremia disseminates the virus to other lymphoid organs. This is 
followed by persistant active viral replication with progressive CD4 + T cell 
depletion latent stage. Hyperplasia of germinal centers with copious amount of 
virion trapped in the follicular dendritic cells in lymph nodes. These trapped 
virions serve as a constant source of infection to CD4 + T lymphocytes in the 
parafollicular area. These trapped virions provide a constant source of cellular 
activation, which results in secretion of IL-1ß, TNF-α, IL-6, which up regulate 
viral replication and expression in infected cells. The architecture of lymph node, 
the thymus and other lymphoid organs is lost as the disease progress. 
 During initial periods of HIV infection, patients have more susceptible CD4 
+ T cells and no HIV–specific immune response. Viral infection is therefore rapid. 
Plasma HIV RNA levels reach more than 10
7
 copies/ml. p24 antigen levels exceed 
100 pg/ml. 
 While HIV specific immunity is evolving, primarily due to the emergence of 
virus specific CD8+ cytotoxic T lymphocytes, plasma RNA levels fall 
precipitously by 2 to 3 logs and symptoms of acute retroviral syndrome resolve. 
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Plasma HIV RNA levels will stabilize at a particular set-point within six months of 
infection in the absence of antiretroviral therapy. 
 A few HIV – positive individuals have normal CD4 counts and low or 
undetectable plasma viraemia even in the absence of appropriate therapy are 
classified as long-term non-progressors. A new term for such individuals is 
―Controller‖ implying their ability to control viral replication without antiretroviral 
therapy. 
Chronicity of Infection: 
 HIV has an extraordinary ability to mutate especially v3 region of gp-120, 
hence escapes from immune defense mechanisms like neutralizing antibodies. 
Cytolytic CD8 + T lymphocytes need CD4 + lymphocytes help in induction and 
maintenance of Cytolytic CD8 + T cell responses. With depletion of CD4 + T 
cells, the functions of CD8 + T cells are reduced. Due to overwhelming exposure 
of viral antigen, CD8 + T lymphocytes gradually reduce in number. A large pool of 
latently infected cells is present which are quiescent and activation may express the 
HIV virus. 
Role of Chronic Cellular activation: 
 Persistent infection causes hypergammaglobulinemia due to hyperactivation 
of B-lymphocytes. Activation of CD4 + T lymphocytes, monocytes and CD8 + T 
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lymphocytes results in increase in proinflammatory cytokines. Proinflammatory 
cytokines increase the expression of HIV in infected cells. 
Role of Cytokines in HIV Pathogenesis: 
 Proinflammatory cytokines like tumor necrosis factor α (TNF - α) , 
Interleukin - 1ß, Interleukin 6(IL-6) are the most potent inducers of HIV 
expression. (NF-KB) the transcriptional activators of HIV expression are activated 
by TNF α. Interferon α and ß suppress HIV replication. Interleukin 10 inhibits 
multiplication of HIV in acutely infected monocytes by blocking secretion of TNF 
α and IL-6. 
 Chemokines – RANTES, macrophage inflammatory protein (MIP) - 1α and 
MIP -1ß inhibit infection by and spread of macrophage tropic/R5 HIV strains, 
which block the CCR5 co-receptor. They are secreted by natural killer cells. 
Stromal cell derived factor (SDF)-1 inhibits infection by and spread of T cell 
tropic/X4 HIV strains which block CXCR4 co-receptor on the target cells. 
 In HIV infection, Type I T-Helper response that upregulates cellular 
immunity is reduced IL-2 and IL-12 stimulate lytic activity and proliferation of 
Cytotoxic T lymphocytes and natural killer cells. 
 HIV – infected individuals have loss of IL-2 receptors and reduced ability to 
produce IL-12 and Interleukin 2. 
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Dysfunction and Depletion of CD4 + T lymphocytes: 
 The hallmark of HIV disease is dysfunction of CD4 + T cells, both 
qualitative and quantitative defects are seen. Some early abnormalities noted are 
loss of response to remote recall antigens like influenza, tetanus toxoid etc. This is 
followed by loss of proliferative response of T cells to alloantigen and later to 
mitogenic stimulus. 
Mechanism of CD4 + T cell depletion & Dysfunction: 
A) Direct Mechanisms: 
 Single cell killing due to direct infection with HIV is less likely to be a major 
contributor for immune dysfunction at least in early HIV infection. The Proportion 
of HIV infected CD4 + T cells in peripheral blood ranges from 1 to 10,000 in early 
infection to 1 in 100 cells in advanced stages. 
Accumulation of Unintegrated Viral DNA 
High intracellular levels of Viral DNA, interferes with signal transduction 
Viral budding results in loss of plasma membrane integrity. 
HIV infected cells may be killed by virus specific immune responses. 
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B) Indirect Mechanisms: 
 Syncytium formation results from fusion of cell membranes of infected and 
uninfected CD4 + T cells have been observed in vitro. 
 Molecular mimicry between Class II MHC and gp-120 results in auto 
antibodies to self MHC determinants and elimination of these cells. 
 Elimination of uninfected CD4 + T cells coated with HIV gp-120 by HIV 
specific immune response called ―Innocent bystander killing‖. 
Apoptosis: 
 Gp-120 and CD4 interaction causes a state of altered cell activation wherein a 
second activation signal like antigen binding of T cell receptor triggers further 
apoptosis. Viral Tat protein also up regulates Fas ligand (CD95) which results in 
apoptotic cell death. 
 Infection of thymocytes and CD34 + bone marrow progenitor cells leads to 
depletion of T cell precursors. Thymic microenvironment I disrupted. 
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Abnormalities of other cells of immune system: 
CD8 + T lymphocytes: 
 Initially there will be a robust cytotoxic response but this wanes gradually in 
later stage. These cells lose functional capability of cytolytic activity and develop 
abnormal phenotype in advanced HIV disease. CD4 + T helper lymphocytes are 
necessary for inducing and maintaining cytotoxic lymphocyte response. 
B lymphocytes: 
 Polyclonal B cell activation by HIV or its products like gp-41 results in 
hypergammaglobulinemia. B cells are also functionally defective and respond 
poorly to immunization. These defects make the person more susceptible to certain 
bacterial infections. 
Monocytes/Macrophages: 
 Though HIV can replicate in monocyte lineage cells, it has little cytopathic 
effect on them. Defects in antigen presentation and decreased secretion of 
cytokines are functional deficits seen in Macrophages/Monocytes. 
Natural killer cells: 
 They are normal in function and number and serve as important source of 
HIV inhibitory chemokines. 
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CLINICAL CATEGORIES OF HIV INFECTION 
CLINICAL EVENT CLINICAL 
DIAGNOSIS 
DEFINITIVE 
DIAGNOSIS 
CLINICAL STAGE 1 
Asymptomatic No HIV-related 
symptoms reported and 
no signs on examination 
Not applicable 
Persistent generalized 
lymphadenopathy 
Painless enlarged lymph 
nodes >1cm in two or 
more non-contiguous 
sites (excluding 
inguinal) in the absence 
of known cause and 
persisting for three 
months or more 
Histology 
CLINICAL STAGE 2 
Moderate unexplained weight 
loss (<10% of body weight) 
Reported unexplained 
involuntary weight loss 
in pregnancy failure to 
gain weight 
Documented weight 
loss <10% of body 
weight 
Recurrent upper respiratory 
tract infections (current event 
plus one or more in last six-
month period) 
Symptom complex, 
such as unilateral face 
pain with nasal 
discharge (sinusitis), 
painful inflamed 
eardrum (otitis media) 
or tonsillopharyngitis 
without features of viral 
infection (such as 
coryza or cough) 
Laboratory studies 
where available, such 
as culture of suitable 
body fluid 
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Herpes zoster Painful vesicular rash in 
dermatomal distribution 
of a nerve supply, does 
not cross the midline 
Clinical diagnosis 
Angular cheilitis Splits or cracks at the 
angle of the mouth not 
due to iron or vitamin 
deficiency, usually 
respond to antifungal 
treatment 
Clinical diagnosis 
Recurrent oral ulcerations 
(two or more episodes in last 
six months) 
Aphthous ulceration, 
typically painful with a 
halo of inflammation 
and a yellow-grey 
pseudomembrane 
Clinical diagnosis 
Papular pruritic eruption Papular pruritic lesions, 
often with marked post-
inflammatory 
pigmentation  
Clinical diagnosis 
Seborrhoeic dermatitis Itchy scaly skin 
condition, particularly 
affecting hairy areas 
(scalp, axillae, upper 
trunk and groin) 
Clinical diagnosis 
Fungal nail infections Paronychia (painful red 
and swollen nail bed) or 
onycholysis (separation 
of the nail from the nail 
bed) of the fingernails 
(white discoloration – 
especially involving 
proximal part of nail 
plate – with thickening 
and separation of the 
nail from the nail bed) 
Fungal culture of the 
nail or nail plate 
material 
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CLINICAL STAGE 3 
Unexplained severe weight 
loss (more than 10% of body 
weight) 
Reported unexplained 
involuntary weight loss 
(>10% of body weight) 
and visible thinning of 
face, waist and 
extremities with obvious 
wasting or body mass 
index <18.5 kg/m
2
; in 
pregnancy, the weight 
loss may be masked 
Documented loss or 
more than 10% of 
body weight 
Unexplained chronic diarrhea 
for longer than one month 
Chronic diarrhea (loose 
or watery stools three or 
more times daily) 
reported for longer than 
one month 
Three or more stools 
observed and 
documented as 
unformed, and two or 
more stool tests reveal 
no pathogens 
Unexplained persistent fever 
(intermittent or constant and 
lasting for longer than one 
month) 
Fever or night sweats 
for more than one 
month, either 
intermittent or constant 
with reported lack of 
response to antibiotics 
or antimalarial agents, 
without other obvious 
foci of disease reported 
or found on 
examination; malaria 
must be excluded in 
malarious areas    
Documented fever 
>37.5⁰C with negative 
blood culture, 
negative Ziehl-Nielsen 
stain, negative malaria 
slide, normal or 
unchanged chest X-
ray and no other 
obvious focus of 
infection 
Oral candidiasis Persistent or recurring 
creamy white curd-like 
plaques that can be 
scraped off 
(pseudomembranous) or 
red patches on tongue, 
Clinical diagnosis 
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palate or lining of 
mouth, usually painful 
or tender (erythematous 
form) 
Oral hairy leukoplakia Fine white small linear 
or corrugated lesions on 
lateral borders of the 
tongue that do not 
scrape off   
Clinical diagnosis 
Pulmonary tuberculosis 
(current) 
Chronic 
symptoms:(lasting more 
than 2-3 weeks) cough, 
haemoptysis, shortness 
of breath, chest pain, 
weight loss, fever, night 
sweats, and no clinical 
evidence of 
extrapulmonary disease 
 
Discrete peripheral 
lymph node 
M.tuberclosis infection 
(especially cervical) is 
considered a less severe 
form of extrapulmonary 
tuberclosis   
One or more sputum 
smear positive for 
acid-fast bacilli and/or 
radiographic 
abnormalities 
consistent with active 
tuberculosis and/or 
culture positive for 
Mycobacterium 
Severe bacterial infection 
(such as pneumonia, 
meningitis, empyema, 
pyomyositis, bone or joint 
infection, bacteraemia and 
severe pelvic inflammatory 
disease)  
Fever accompanied by 
specific symptoms or 
signs that localize 
infection and response 
to appropriate antibiotic 
Isolation of bacteria 
from appropriate 
clinical specimens  
Acute necrotizing ulcerative 
gingivitis or necrotizing 
Severe pain, ulcerated 
gingival papillae, 
loosening of teeth, 
Clinical diagnosis 
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ulcerative periodontitis spontaneous bleedin, 
bad odour and rapid loss 
of bone and/or soft 
tissue 
Unexplained anaemia(<8/dl), 
neutropenia(<0.5x10
9 
per 
liter) or chronic(more than 
one month) 
thrombocytopenia(<50x10
9
per 
liter) 
Not presumptive clinical 
diagnosis 
Diagnosed on lab 
testing and not 
explained by other 
non HIV conditions; 
not responding to 
standard therapy with 
hematinics, 
antimalarial agents or 
anthelmintic agents as 
outlined in relevant 
national treatment 
guidelines, WHO 
integrated 
management of 
childhood illness 
guidelines or other 
relevant guidelines   
CLINICAL STAGE 4 
HIV wasting syndrome  Unexplained involuntary 
weight loss (>10% 
baseline body weight), 
with obvious wasting or 
body mass index< 18.5 
 
PLUS 
 
Unexplained chronic 
diarrhea(loose or watery 
stools three or more times 
daily) reported for longer 
than one month 
Documented weight loss 
>10% of body weight 
 
PLUS 
 
Two or more unformed 
stools negative for 
pathogens 
 
OR 
 
Documented temperature 
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OR 
 
Reports of fever or night 
sweats for more than one 
month without other 
cause and lack of 
response to antibiotics or 
antimalarial agents; 
malaria should be 
excluded in endemic 
areas 
of >37.5⁰
 
C with no other 
cause o disease, negative 
malaria slide and normal 
or unchanged chest X ray  
 
 
Pneumocystis pneumonia Dyspnoea on exertion or 
nonproductive cough o 
recent onset (within the 
past three months), 
tachypnoea and fever 
 
AND 
 
Chest X-ray evidence of 
diffuse bilateral 
interstitial infiltrates 
 
AND 
No evidence of bacterial 
pneumonia; bilateral 
crepitations on 
auscultation with or 
without reduced air entry 
Cytology or 
immunofluorescent 
microscopy of induced 
sputum or 
bronchoalveolar lavage or 
histology of lung tissue. 
Recurrent severe bacterial 
pneumonia 
Current episode plus one 
or more previous 
episodes in the past six 
months; acute onset (<2 
Positive culture or 
antigen test of a 
compatible organism 
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weeks) of severe 
symptoms (such as fever, 
cough, dyspnoea and 
chest pain) PLUS new 
consolidation on clinical 
examination or chest X-
ray; response to 
antibiotics 
Chronic herpes simplex 
virus infection (orolabial, 
genital or anorectal) of 
more than one month or 
visceral infection of any 
duration 
Painful, progressive 
anogenital or orolabial 
ulceration; lesions caused 
by recurrence of herpes 
simplex virus infection 
and reported for more 
than one month. History 
of previous episodes. 
Visceral herpes simplex 
virus requires definitive 
diagnosis  
Positive culture or 
DNA(by polymerase 
chain reaction) of herpes 
simplex virus or 
compatible cytology or 
histology 
Oesophageal candidiasis Recent onset of 
retrosternal pain or 
difficulty on 
swallowing(foods and 
fluids) together with oral 
candida  
Macroscopic appearance 
at endoscopy or 
bronchoscopy, or by 
microscopy or histology 
Extrapulmonary 
tuberculosis 
Systemic illness (such as 
fever, night sweats, 
weakness and weight 
loss). Other evidence for 
extrapulmonary or 
disseminated tuberculosis 
varies by site, such as 
pleura, pericardia, 
meninges, mediastinum 
or abdominal 
 
Discrete peripheral lymph 
M. tuberculosis isolation 
or compatible histology 
from appropriate or 
radiological evidence of 
miliary  TB(diffuse 
uniformly distributed 
small military shadows or 
micronodules on CXR) 
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node mycobacterium 
tuberculosis infection 
(especially cervical) is 
considered a less severe 
form of extrapulmonary 
tuberculosis  
Kaposi sarcoma Typical gross appearance 
in skin or oropharynx of 
persistent, initially flat, 
patches with a pink or 
violaceous colour, skin 
lesions that usually 
develop into plaques or 
nodules 
Macroscopic appearance 
at endoscopy or 
bronchoscopy or by 
histology. 
Cytomegalovirus 
disease(other than liver, 
spleen or lymph node) 
Retinitis only; may be 
diagnosed by experienced 
clinicians. Typical eye 
lesions  on funduscopic 
examination; discrete 
patches of retinal 
whitening with distinct 
borders, spreading 
centrifugally, often 
following blood vessels, 
associated with retinal 
vaculitis, hemorrhage and 
necrosis 
Compatible histology or 
cytomegalovirus 
demonstrated in CSF by 
culture or DNA by PCR  
CNS toxoplasmosis Recent onset of a focal 
nervous system 
abnormality consistent 
with intracranial disease 
or reduced level of 
consciousness AND 
response within 10 days 
to specific therapy  
Positive serum 
toxoplasma antibody 
AND (if available) single 
or multiple intracranial 
mass lesion on 
neuroimaging (computed 
tomography or magnetic 
resonance imaging)  
HIV encephalopathy Disabling cognitive 
and/or motor dysfunction 
Diagnosis of exclusion: 
and (if available) 
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interfering with activities 
of daily living, 
progressing over weeks 
or months in the absence 
of a concurrent illness or 
condition other than HIV 
infection that might 
explain the findings  
neuroimaging (computed 
tomography or magnetic 
resonance imaging) 
Extrapulmonary 
cryptococcosis (including 
meningitis) 
Meningitis: usually 
subacute, fever with 
increasing severe 
headache, meningism, 
confusion, behavioural 
changes that respond to 
cryptococcal therapy 
Isolation of Cryptococcus 
neoformans from 
extrapulmonary site or 
positive cryptococcal 
antigen test on 
cerebrospinal fluid or 
blood 
Disseminated non-
tuberculous myobacterial 
infection 
No presumptive clinical 
diagnosis 
Diagnosed by finding 
atypical myobacterial 
species from stool, blood, 
body fluid or other body 
tissue, excluding the 
lungs  
Progressive multifocal 
leukoencephalopathy 
No presumptive clinical 
diagnosis 
Progressive nervous 
system disorder 
(cognitive dysfunction, 
gait/speech disorder, 
visual loss, limb 
weakness and cranial 
nerve palsies) together 
with hypodense white 
matter lesions on neuro-
imaging or positive 
polyomavirus JC positive 
polymerase chain 
reaction on cerebrospinal 
fluid 
Chronic cryptosporidiosis 
(with diarrhea lasting 
No presumptive clinical Cysts identified on 
modified Ziehl-Nielsen 
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more than one month) diagnosis stain microscopic 
examination of unformed 
stool 
Chronic isosporiasis No presumptive clinical 
diagnosis 
Identification of Isospora 
Disseminated mycosis 
(such as coccidiomycosis, 
histoplasmosis or 
penicilliosis) 
No presumptive clinical 
diagnosis 
Histology, antigen 
detection or culture from 
clinical specimen or 
blood culture 
Recurrent non-typhoid 
Salmonella bacteraemia 
No presumptive clinical 
diagnosis 
Blood culture 
Lymphoma (cerebral or 
B-cell non-Hodgkin) 
No presumptive clinical 
diagnosis 
Histology of relevant 
specimen or, for central 
nervous system tumours, 
neuroimaging techniques 
Invasive cervical 
carcinoma 
No presumptive clinical 
diagnosis 
Histology or cytology 
Visceral leishmaniasis No presumptive clinical 
diagnosis 
Diagnosed by histology 
(amastigotes visualized) 
or culture from any 
appropriate clinical 
specimen 
HIV-associated 
nephropathy 
No presumptive clinical 
diagnosis 
Renal biopsy 
HIV-associated 
cardiomyopathy 
No presumptive clinical 
diagnosis 
Cardiomegaly and 
evidence of poor left 
ventricular function 
confirmed by 
echocardiography 
 
Table 2: Clinical Categories of HIV Infection 
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Diagnosis of HIV Infection: 
 The diagnosis of HIV infection depends as the direct detection/demonstration 
of antibodies to HIV or one of its components. Generally the antibodies to HIV 
appear in the circulation 3-12 weeks following infection. 
ELISA: 
 Also referred as Enzyme immuno assay is the standard blood screening test 
for HIV infection with a sensitivity of >99.5% 
 Commercial EIA kit that most diagnostic laboratories contains antigens from 
both HIV-I and HIV-II and thus able to detect either. The fourth generation EIA 
tests combine detection of antibodies to HIV with detection of p24 antigen to HIV. 
While EIA is an extremely sensitive test, it is not optimal with specificity 
especially in studies of low-risk individuals such as volunteer blood donors. 
Factors that all associated with false positive EIA tests are antibodies to class II 
antigens such as may be seen following pregnancy, blood transfusion or 
transplantation, auto antibodies, hepatic disease, recent influenza vaccination and 
acute viral infections. For these reasons, anyone suspected of having HIV infection 
based on a inconclusive EIA or positive EIA result must have the result confirmed 
with a more specific assay such as Western blot. 
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Western blot: 
 This is the most commonly used confirmatory test. A Western blot 
demonstrates antibodies to product of all three of the major genes of HIV (Gag, Pol 
and Env) are confirmative evidence of HIV infection. While the western blot is an 
excellent confirmatory test for HIV infection in patients with a positive or 
indeterminate EIA, it is a poor screening test. In 1993, the U.S. FDA established 
the criteria for a positive western blot state if antibodies to two of these HIV 
proteins p24, gp41and gp120/160 were present. In addition, the diagnosis of HIV 
can be confirmed with p24 antigen capture assay or one of the tests for HIV RNA. 
p24 antigen capture assay: 
 This is the simplest of the direct detection tests in an EIA based format. The 
p24 antigen capture assay has its greatest use as a screening test for HIV infection 
in patients suspected of having the acute HIV syndrome as high levels of p24 
antigen are seen prior to the development of antibodies during the first few weeks 
of infection. This test is positive in 50% of patients and detects down to 15pg/ml of 
p24 protein. 
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Other Direct Detection tests of HIV: 
 These tests measure and monitor levels of HIV RNA in the plasma of 
patients with HIV infection. These assays are predominantly used for this purpose. 
HIV RNA by reverse transcriptase PCR: 
 PCR amplification of CDNA generated from viral RNA(target amplification) 
 Can reliably detect 40 copies/ml of HIV RNA. 
HIV RNA by bDNA(branched DNA): 
 Measures particle associated HIV RNA in a nucleic acid capture assay 
employin signal amplification. 
 Can reliably detect 50 copies/ml of HIV RNA. 
HIV RNA by NASBA (Nucleic acid sequence based amplification): 
 Uses the technique of isothermic nucleic acid amplification with internal 
controls. 
 Can reliably detect 80 copies/ml of HIV RNA. 
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TREATMENT: 
General Principles of Patient Management: 
 Once a diagnosis of HIV infection was made, detailed clinical examinations 
and lab studies are done to know the severity of disease and to know the baseline 
parameter of that particular individual.  
Initial Evaluation of the Patient with HIV Infection: 
 History and physical examination 
 Routine chemistry and hematology 
 AST, ALT, direct and indirect bilirubin 
 Lipid profile and fasting glucose 
 CD4+ T lymphocyte count 
 Two plasma HIV RNA levels 
 HIV resistance testing 
 HLA-B5701 screening 
 RPR or VDRL test 
 Anti-Toxoplasmosis antibody titer 
 PPD skin test 
 Mini-Mental Status Examination 
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 Serology’s for hepatitis A, hepatitis B, and hepatitis C 
 Immunization with pneumococcal polysaccharide; influenza as indicated 
 Immunization with hepatitis A and hepatitis B if seronegative 
 Counseling regarding natural history and transmission 
 Help contacting others who might be infected 
 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
VDRL, Venereal Disease Research Laboratory; RPR, rapid plasma reagin; PPD, 
purified protein derivative; 
 
Antiretroviral therapy: 
 ART drugs can be divided into four categories 
 RTIs(Reverse transcriptase inhibitors) . 
 Nucleoside and nucleotide RTIs. 
 Non nucleoside RTIs. 
 PIs(Protease inhibitors) 
 Integrase inhibitors 
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 Viral entry inhibitors 
 CCR5 antagonists 
 Fusion inhibitors 
Principles of Therapy of HIV infection: 
1. Ongoing HIV replication leads to immune system damage and progression to 
AIDS. 
2. Plasma HIV RNA levels indicate the magnitude of HIV replication and the rate 
of CD4+ T cell destruction. CD4+ T cell counts indicate the current level of 
competence of the immune system. 
3. Rates of disease progression differ among individuals, and treatment decisions 
should be individualized based on plasma HIV RNA levels and CD4+ T cell 
counts. 
4. Maximal suppression of viral replication is a goal of therapy; the greater the 
suppression the less likely the appearance of drug-resistant quasispecies. 
5. The most effective therapeutic strategies involve the simultaneous initiation of 
combinations of effective anti-HIV drugs with which the patient has not been 
previously treated and that are not cross-resistant with antiretroviral agents that the 
patient has already received. 
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6. The antiretroviral drugs used in combination regimens should be used according 
to optimum schedules and dosages. 
7. The number of available drugs is limited. Any decisions on antiretroviral 
therapy have a long-term impact on future options for the patient. 
8. Women should receive optimal antiretroviral therapy regardless of pregnancy 
status. 
9. The same principles apply to children and adults. The treatment of HIV-infected 
children involves unique pharmacologic, virologic, and immunologic 
considerations. 
10. Compliance is an important part of ensuring maximal effect from a given 
regimen. The simpler the regimen, the easier it is for the patient to be compliant 
Classification of ARV Drugs: 
Nucleoside/Nucleotide reverse transcriptase inhibitors: 
 Lamivudine (3TC) 
 Didanosine (DDI) 
 Zidovudine (AZT) 
 Emtricitabine(FTC) 
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 Zalcitabine (DDC) 
 Tenofovir 
 Stavudine (D4T) 
 Abacavir 
Non Nucleoside RTIs: 
 Nevirapine (NVP) 
 Delavirdine (DLV) 
 Rilpivirine 
 Efavirenz (EFV) 
 Etravirine 
Protease inhibitors: 
 Lopinavir (LPV) 
 Indinavir (IDV) 
 Amprenavir (APV) 
 Fosamprenavir (FPV) 
 Ritonavir (RTV) 
 Atazanvir (ATV) 
 Saquinavir (SQV) 
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 Darvnavir (DRV)  
 Tipranavir (TPV) 
 Nelfinavir (NFV) 
 Entry inhibitors: 
 Enfuvirtide (ENF) 
 Maraviroc (MVC) 
Integrase inhibitors: 
 Raltegravir (RAR) 
 Elvitegravir 
Criteria for Starting ART in HIV patients: 
1. Acute HIV syndrome 
2. Chronic infections 
A. Symptomatic patients includes HIV-associated nephropathy  
B. Asymptomatic patients  
1. CD4+ T cell count <500/L
a
  
2. Pregnancy 
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3. Post exposure prophylaxis 
a  
 - controversial area some start treatment regardless of CD4+ count 
TREATMENT IN SPECIFIC SITUATIONS: 
HIV AND TUBERCULOIS: 
 Start Efavirenz based regimen 
 Start ART for all patients irrespective of CD4 count 
 Start TB treatment first and when it is tolerated start ART and within first 8 
weeks 
 
HIV AND PREGNANCY: 
      WHO stages I and II: start ART at CD4<350 cells/mm
3 
      WHO stages III and IV: start ART irrespective of CD4 count 
HIV + HBV: 
 If treatment is not indicated for either infection, monitor patient. 
 If treatment is indicated for HIV, then start with TDF + 3TC/FTC – based 
regimen along with Efavirenz. 
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 If treatment is indicated only for HBV, then Peg interferon is recommended. 
HCV treatment: 
 HCV infection increases the risk of developing hepatic toxicity of 
antiretroviral treatment. 
 First start ART and when CD4 rises to >350 cells/m3, anti-HIV is considered. 
 Treatment of HCV is with Peg-interferon & Ribavirin. 
 Avoid AZT or Didanosine as they are contraindicated with Ribavirin. 
Indications for Changing HAART regimen in HIV patients
 
 Following the initiation of therapy drop in plasma HIV RNA levels by less 
than 1 log in 4 weeks 
 Significant increase in plasma HIV RNA levels defined as threefold or 
greater, that is not attributable to intercurrent infections, testing methods  
 Continuously decreasing CD4+ T cell count 
 Clinically deteriorating patients 
 Side effects  
 the change should be starting at least two effective drugs except in drug 
toxicity where single drug  substitution is acceptable  
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Toxicity of Commonly Used Antiretroviral Drugs: 
Zidovudine: 
Anemia, granulocytopenia, lipid abnormalities, lipoatrophy, hepatomegaly, 
steatosis, headache, nausea, nail pigmentation, lactic acidosis, hyperglycemia, 
myopathy. 
Stavudine: 
Peripheral neuropathy, ascending neuromuscular weakness, hepatomegaly, 
lactic acidosis, steatosis, lipodystrophy, lipid abnormalities, pancreatitis, 
hyperglycemia. 
Didanosine: 
Lactic acidosis, Pancreatitis, nausea, abnormalities on liver LFT, 
hepatomegaly with steatosis, optic neuritis, peripheral neuropathy, hyperglycemia 
Zalcitabine: 
Oral ulcers, pancreatitis, peripheral neuropathy, lactic acidosis, steatosis.  
Lamivudine: 
Flare of hep B co infection after discontinuing drug 
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Emtricitabine: 
Skin discoloration, Hepatotoxicity 
Abacavir: 
Hypersensitivity reactions especially in HLA-B5701+ persons (can be fatal); 
nausea, vomiting, fever, rash, loss of appetite, and malaise or fatigue.  
Tenofovir: 
Renal osteomalacia, Hep B flare after discontinuation in coinfected persons 
Delavirdine: 
Skin rash, abnormalities in liver function tests 
Nevirapine: 
Skin rash, hepatotoxicity 
Efavirenz: 
Potentially teratogenic, rash, elevated liver function tests, lipid 
abnormalities, drowsiness, abnormal dreams, dysphoria, depression. 
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Etravirine: 
Rash, nausea, hypersensitivity reactions 
Rilpivirine: 
Nausea, dizziness, somnolence, vertigo, less CNS toxicity and rash than 
Efavirenz 
Protease Inhibitors: 
Abdominal pain, abnormal stools, weakness, headache, hyperglycemia, 
hypertriglyceridemia, hyperuricemia, lipodystrophy. 
Enfuvirtide: 
Hypersensitivity reactions, Local injection reactions, increased incidence of 
bacterial pneumonia. 
Maraviroc: 
Hepatotoxicity, abdominal pain, fever, , musculoskeletal symptoms,  cough, 
rash, dizziness, nasopharyngitis. 
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Raltegravir:  
Rhabdomyolysis, diarrhea, Nausea, headache, CPK elevation, muscle 
weakness.  
Plasma Lipids and Lipoproteins: 
There are lot of studies to prove the association between dyslipidemia and 
atherosclerosis. Current understanding of physiology and pathology of plasma 
lipids is based mainly on the concept of plasma lipoproteins and the form in which 
they circulate in the blood.  
Chemistry of Lipids: 
The lipids constitute a wide range of substances of biological origin. These 
are soluble in organic solvents and are poorly soluble in water. Metabolically lipids 
are more closely interrelated, being transported together in the plasma lipoproteins 
and sharing certain regulatory mechanisms.  
Lipids can be classified as follows:  
Total Lipids  
Simple Lipids                                                     Complex Lipids  
1. Fatty acids                                                      1. Triglycerides  
2. Sterols: cholesterol                                         2. Cholesterol esters 
         Steroid hormones                              3. Phospholipids 
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  Vitamin D     4. Sphingolipids 
 3. Terpenes(carotenes, Vit-A,E & K)  5. Waxes  
 4. Prostaglandins 
Fatty Acids: 
They are present as such in minute concentrations in plasma and cells. They 
are constituents of most lipid classes. They contain a carboxylic acid group and 
hydrocarbon chains are thus aliphatic monocarboxylic acids. The fatty acids are 
grouped into saturated and unsaturated fatty acids depending on the absence or 
presence of a double bond respectively. The main saturated fatty acids are palmitic 
and stearic acids. Most of the fatty acids are carried mainly by albumin. Essential 
fatty acids are those which cannot be synthesized in the body. Free fatty acids are 
immediately available energy sources and provide much of the energy 
requirements of the body. (Normal values range from 250-400 mg/dI).  
Cholesterol:  
Cholesterol has a steroid structure i.e., perhydro cyclo pentano phenanthrene 
ring. Cholesterol has twenty seven carbon atoms. Cholesterol is by far the most 
abundant sterol in human tissues. The adult human body contains about 150gms. It 
is the precursor of bile acids, steroid hormones and vitamin D and has an important 
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structural role mainly in cellular but to a small extent also in intracellular 
membranes.  
The tissue cholesterol is largely in 'free' (non-esterified) form, while in plasma; 
about 60-70% is present as cholesteryl esters. In man this esterification occurs in 
plasma, due to the circulating enzyme, lecithin cholesterol acyl transferase 
(LCAT). The fatty acid is transferred from the 2nd position of lecithin to 
cholesterol. For routine clinical purposes, the estimation of total cholesterol is 
adequate. (Normal values range from 150-200 mg/dl).  
Triglycerides:  
(Neutral fats or fats) are compounds of one molecule of glycerol united by 
ester bonds to three molecules of fatty acids. If only one or two of the three 
hydroxyl groups of glycerol is esterified then they are called mono or diglycerides 
respectively. Triglycerides are an important energy store. Plasma triglycerides are 
derived from two sources. Exogenous or dietary triglycerides are derived from 
food and circulate in the plasma in the form of chylomicrons. These are large, low 
density particles which are formed in intestinal epithelial cells and appear in the 
plasma soon after a meal. Chylomicrons deliver dietary triglycerides to the adipose 
and other tissues. In normal individuals, they are entirely cleared from the plasma 
within 12 hours of fasting.  
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Endogenous triglycerides are derived primarily from hepatic conversion of 
carbohydrate and amino acids. Eighty percent of it circulates in plasma in the form 
of very low density lipoproteins (VLDL), which transport triglycerides to adipose 
and other tissues. As triglycerides are removed, intermediate density lipoproteins is 
formed, some of which undergoes catabolism in the liver to low density lipoprotein 
(LDL) particles. A small proportion (approximately 15 percent) of plasma 
triglycerides are carried in LDL and a tiny fraction is contained in the high density 
lipoprotein (HDL) moieties. 
The 1984 Consensus Panel divided plasma triglyceride levels into three 
categories: ―normal‖ was defined as a TG level less than 250 mg/dl and HTG was 
dichotomized into ―borderline hypertriglyceridemia‖ (250 to 500 mg/dl) and ―true 
hypertriglyceridemia‖ (>500 mg/dl). Levels of TG greater than 1000 mg/dl are 
usually due to chylomicronemia and are believed to be able to cause recurrent 
abdominal pain and pancreatitis. 
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Fig. 5: Exogenous and Endogenous Transport of Lipids 
Elevated triglycerides are clinically important owing to their direct 
relationship to pancreatitis, and their association with glucose intolerance and renal 
and hepatic disease. Triglyceride measurements, as part of lipid evaluation for 
atherosclerotic risk, are important as they provide the only convenient and cost-
effective method for routinely estimating LDL cholesterol. Their inverse 
relationship to HDL makes triglyceride measurements a cost effective screening 
procedure. Unlike cholesterol measurements, triglycerides should always be 
assessed in the fasting state.  
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Phospholipids: 
They are complex lipids resembling triglycerides, but in addition to glycerol 
and fatty acids, they contain one or more phosphoric acid groups and a nitrogenous 
base. The major phospholipids in plasma are lecithin and sphingomyelin. The 
phosphate and nitrogenous base are water soluble, a fact that is important in lipid 
transport. (Normal values range between 150-275 mgs %).  
The Lipoproteins of Plasma: 
Lipids are insoluble in water. When lipids combine with water soluble 
complex proteins, they become soluble and constitute lipoproteins.  
The role of protein-lipid complexes in maintaining the lipids in solution in plasma 
was suspected by Schulz (1897) and Nerking (1901) at the turn of 20
th 
century. 
Precipitation of a lipoprotein from horse serum was achieved in 1929 by 
Macheboeuf. Application of new physical methods for protein separation, 
including electrophoresis and ultra centrifugation expedited the progress in 
lipoprotein chemistry. Tiselius et al in 1941 reported the existence of two 
lipoprotein classes, separable by moving boundary electrophoresis. These were 
alpha and beta lipoproteins. It was another decade before a further component, Pre-
B lipoprotein was identified by zonal electrophoresis (Dangerfield WO, 1955). 
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Lipoprotein Electrophoretic Mobility Major 
Apolipoprotein 
Chylomicrons Origin 
 
Apo B – 48 
 
Chylomicron 
remnants 
Slow pre – ß 
 
Apo B – 48 
 
VLDL Pre – ß Apo B – 100 
IDL Slow pre – ß 
 
Apo B – 100 
 
LDL ß 
 
Apo B -100 
 
HDL Α Apo A - I 
Lp(a) Pre – ß Apo B - 100 
 
Table 3: Major Lipoprotein Classes 
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Structure of Lipoprotein Particle:  
The lipoproteins are high molecular weight globular proteins that transport 
non polar lipids in the plasma. Each lipoprotein particle contains a non polar core, 
and a polar coat. The core consists of varying amounts o triglycerides and 
cholesterol esters forming bulk of the particle. The polar coat consists of 
phospholipids and apolipoprotein. The phospholipids stabilize the lipoprotein 
particles so that it can remain attached to unesterified cholesterol. The 
apolipoproteins are partly exposed on the surface so that it directs the lipoprotein to 
the site of its metabolism either by binding to specific enzymes or transport 
proteins on cell membranes. 
Among the many techniques used to separate lipoproteins, the following are 
important.  
1. Ultracentrifugation:  
There are two principle ways of using ultracentrifugation to determine 
lipoproteins. They employ two different instruments. The preparative and the 
analytical centrifuge.  
a) Preparative ultracentrifugation: Plasma has a salt density of about 1.006. 
Ultracentrifugation of plasma without adjustment of its density for a short 
period brings the chylomicrons rapidly to the top of the tube. Longer 
ultracentrifugation at this density allows the VLDL to be collected on the 
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surface. Addition of salt to plasma will further raise the density to selected 
levels and permit isolation of other lipoproteins. Those lipoproteins, which 
are separated below a density of 1.006 constitute VLDL, in the density range 
of 1.006 to 1.063 constitute LDL and in the density range of 1.063 to 1.21 
constitute HDL.  
b) Analytical Centrifugation: In this instrument, plasma fraction usually prepared 
at salt density of 1.063 is centrifuged at high speeds and the moving bands of 
the floating lipoproteins are serially photographed and later used to 
determine the concentrations that are referred to certain standard conditions.  
2. Electrophoresis:  
If the plasma is examined by paper or agarose gel electrophoresis at pH 8.6, 
it is possible to demonstrate, by means of fat stains, the existence of four bands. 
Three of these move towards the anode and one remains at the origin, that is, the 
line of application of the serum. The faster moving band occurs approximately in 
the same position as alpha-l globulin. It is known as alpha-lipoprotein and 
corresponds to the HDL fraction, demonstrated by ultracentrifugation floatation 
technique. The next band appears at approximately the position of beta-globulin 
and is known as beta lipoprotein, which corresponds to LDL fraction. Another 
band appears between the position of alpha globulin and beta globulin. It is known 
as pre-beta lipoprotein which corresponds to VLDL fraction. The band, which 
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remains stationary at the origin, consists of the chylomicrons. The five principal 
lipoprotein classes are defined according to their density on ultracentrifugation and 
by their mobility on agarose gel electrophoresis. In addition, they can be classified 
on the basis of size and relative concentrations of cholesterol or triglyceride and by 
their apoprotein content. The major lipoprotien classes are high-density 
lipoproteins (HDLs), intermediate-density lipoproteins (IDLs), low density 
lipoproteins (LDLs), very low-density lipoproteins (VLDLs), and chylomicrons.   
Chylomicrons:  
Chylomicrons are the largest of the lipoproteins. Their primary function is to 
transport dietary, or exogenous, triglycerides and cholesterol from the intestinal 
lumen to the sites of metabolism or storage. The chylomicrons are formed in the 
gastrointestinal (GI) tract. In the lumen of the GI tract, dietary fat is degraded into 
free fatty acids and monoglycerides. These substances enter the intestinal villi, 
where they are reconstructed into a triglyceride particle. Dietary cholesterol 
absorbed into the intestinal wall is then esterified to cholesteryl esters, mainly 
cholesteryl oleate, by the enzymatic reaction catalyzed by cholesterol acyl 
transferase. The triglyceride and cholesteryl esters are then combined with apos 
beta-48, A-I and A-IV within the intestinal wall to form chylomicron particles.  
The nascent chylomicrons enter the systemic circulation by the way of 
lymphatics. Apos E and C are then added to the particles. Normally, the 
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chylomicrons are cleared rapidly from the blood and are virtually absent in the 
fasting state. The clearing of the chylomicrons is modulated by the enzyme 
lipoprotein lipase (LPL). Lipoprotein lipase catalyzes hydrolysis of the triglyceride 
core of the chylomicron, leaving a remnant particle rich in cholesterol, apo C, apo 
E, and apo B-48. During this process, apoproteins, phospholipids, and cholesterol 
from the surface of the chylomicron are transferred to HDL particles. The 
chylomicron remnants are cleared rapidly from the circulation by receptors present 
on the surface of liver cells. These receptors recognize the apo E component of the 
remnant particles. Remnants that contain the apo E2 moiety bind less well, and are 
thus removed less quickly than remnants that contain either the apo E3 or E4 
moiety. Chylomicron remnants are thought to be atherogenic, and an abnormal 
delay in their clearance is therefore undesirable. Delay in chylomicron clearance 
may be secondary to a genetically inherited deficiency of LPL or its activator, apo 
C-II. It is partial degradation of the chylomicron to a remnant that renders the 
particle atherogenic. Delayed clearance of the remnant particles may damage the 
vascular endothelium, and thus predispose to atherosclerosis.  
Hyperchylomicronemia also may be secondary to other acquired 
hypertriglyceridemic states, such as those seen with exogenous estrogen use, 
uncontrolled diabetes, and excessive alcohol intake. The presence of chylomicrons 
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in the serum is necessary for the diagnosis of type I or V hyperlipoproteinemia in 
the Fredrickson and less classification system.  
 
Very Low-Density Lipoprotein: 
VLDLS are intermediate in size between chylomicrons and IDLS. They are 
relatively large particles, with diameters ranging from 500 to 800 A. VLDLS are 
produced in the liver. Their primary lipid component is triglyceride, but 
cholesterol, cholesteryl ester, and phospholipid are also present. Their surface 
components are apo B-100, C and E and phospholipid. The synthesis of VLDL is 
increased by excess carbohydrate, alcohol, or caloric consumption. The function of 
VLDL is to transport endogenously synthesized cholesterol and triglycerides to the 
peripheral tissues, where the fatty acids can be utilized for energy or stored as 
triglycerides.When VLDL particles enter the systemic circulation, their triglyceride 
core is hydrolyzed by LPL. As the VLDL particle is degraded, most of its surface 
apoproteins, except for apo B-100, are transferred with other surface components 
to HDL. The remaining VLDL remnant is called IDL. Unlike the chylomicron 
remnant, IDL contains apo B-100 rather than apo B-48. The metabolism of VLDL 
is complex and not fully understood. Some of the larger particles appear to be 
directly removed from the circulation. The rest of the particles enter the cascade, in 
which they are converted to IDL and eventually to LDL.  
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Intermediate Density Lipoprotein: 
IDLs, which carry both cholesterol and triglyceride, are the products of the 
enzymatic (LPL-medicated) breakdown of VLDL. After their formation, IDLs may 
be removed by the liver by means of the binding of apo E to the LDL or B/E 
receptor. The remainders are converted to LDL, a process, thought to be mediated, 
by hepatic triglyceride lipase. IDLs have high cholesterol content and migrate in 
the beta region on electrophoresis. Elevations of IDSs are thought to predispose to 
premature CAD and peripheral artery disease. Accumulation of IDL is 
characteristic of dysbetalipoproteinemia, also called Fredrickson's type III 
hyperlipoproteinemia. This relatively uncommon form of hyperlipoproteinemia is 
associated with both triglyceride and cholesterol elevations.  
Low Density Lipoprotein: 
LDL, which is 45 percent cholesterol by weight, is the major carrier of 
cholesterol to the nerve tissue, cell membranes and other cells that require the 
cholesterol for metabolic functions, including the synthesis of steroid hormones. 
LDLs have a density of 1.019 to 1.063 gm/ml a diameter of 180 to 280 A, and beta 
electrophoretic mobility. LDL usually is formed from VLDL breakdown. Direct 
synthesis has not been completely excluded. Increase LDL synthesis may occur be 
means of enhanced conversion of VLDL remnants or direct hepatic production of 
apo B containing lipoproteins.  
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Apo B-I00 is the only protein found in LDL, and makes up about 20 percent 
of the LDL mass. Each particle is thought to contain 1 molecule of apo B- 100, but 
the ratio of protein mass to total particle mass can vary from the large to the small 
particle range. LDL particles are heterogeneous, differing in their hydrated density 
and cholesteryl ester in the LDL particle, for example, may vary upto 40 percent 
by weight. Patients with greater concentration of small, dense LDL, have been 
reported to have a three times greater risk for acute myocardial infarction (MI), 
regardless of weight or gender. Small, dense LDL molecules are commonly 
associated with male gender, diabetes, depressed HDL levels and familial 
combined hyperlipoproteinemia.  
LDL particles are recognized by specific LDL or apo B/E receptors on the 
surfaces of hepatic and certain non hepatic cells. These receptors also recognize 
and bind some of the apo E containing IDL particles, preventing their conversion 
into LDL. Bound LDL particles (and IDL particles) are then internalized into the 
cells. About 75 percent of the LDLs in the bloodstream are removed by this 
specific receptor mediated binding. The reminding LDL particles are cleared by 
scavenger or macrophage receptors or by non receptor mediated mechanism. The 
number of LDL receptors is not fixed, and can be modified by genetic defects, 
saturated fat and cholesterol intake or certain pharmacological agents.  
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The prototype disease involving the LDL receptor is familial 
hypercholesterolemia. In this condition, heterozygotes have a 50 percent reduction 
in LDL receptors, whereas homozygotes have little or no receptor activity. Familial 
hypercholesterolemia is fairly common, occurring in 1 in every 500 people. 
Familial combined hyperlipidemia (FCR) is even more common, possibly 
occurring in 1 in every 500 people. Clinically, FCR patients may be difficult to 
differentiate from those with familial hypercholesterolemia. In FCR, most patients 
lack tendon xanthomas; most family studies show varying Fredrickson's 
phenotypes.  
The characteristic defect in FCR is thought to be an overproduction of apo 
B- 100 by the liver. Also, FCH patients have a lower ratio of apo A-I to apo B- 
100. About 80 percent of patients with an elevated LDL value do not have only 
one gene defect; the dyslipidemia is secondary to polygenic factors. Hence, 
elevations of LDL due to primary receptor defects are relatively uncommon.  
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Phenotype  Lipoprotein Abnormality  Result  
Type I  Chylomicrons elevated  Very high TG  
Type IIa  LDL elevated  High cholesterol  
Type IIb  LDL and VLDL elevated  High cholesterol and TG  
Type III  IDL elevated  High cholesterol and TG  
Type IV  VLDL elevated  High TG, normal to slightly 
high cholesterol  
Type V  Chylomicrons present and VLDL 
elevated  
Very high TG and 
Cholesterol  
 
Table 4: Fredrickson Classification of Hyperlipidemia 
 
High Density Lipoprotein: 
HDLs are produced by the liver and the GI tract and by the peripheral 
catabolism of chylomicrons and VLDLs. HDL particles carry cholesteryl ester as 
their major lipid and apos A-I and A-II as their major proteins. Much of the 
apoprotein component of HDL is transferred in the systemic circulation to VLDLs 
or chylomicrons. Apo C-II an obligatory activator of LPL, is one of the apoproteins 
transferred by HDL. By weight, HDL particles are about 30 percent cholesterol, 45 
percent protein, and 25 percent phospholipid (predominantly phophatidyl choline). 
Small amounts of triglycerides are present.  
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HDL particles exist in several subtypes. For clinical purposes, HDL
2 
and 
HDL
3 
are the major circulating sub fractions. HDL
2
, which migrates with alpha 
mobility, is the subfraction, most closely associated with statistical protections 
against premature atherosclerosis. It has a density of 1.061 to 1.201 gm/ml and a 
diameter of 90 to 120 A. HDL
3 
is a smaller particle, with a density of 1.125 to 
1.210 gm/ml and a diameter of 50 to 90 A. Alcohol consumption increases both 
HDL subfractions, with a greater impact on HDL
3 
Lower levels of both 
subfractions are associated with male gender, hyper triglyceridemia, diabetes 
mellitus, obesity, uremia, the use of androgens, progestins, and tobacco products; 
and diets rich in polyunsaturated fats but low in total fat content.  
Several epidemiological studies have addressed the debate whether there is a 
varying clinical impact on CAD depending on the relative levels of HDL
2 
and 
HDL
3. 
In males with CAD who have an associated low level of circulating HDL, 
both fractions of HDL are depressed with more of a decline in HDL
2
.  
HDL particles participate in the reverse transport of free cholesterol from 
peripheral tissues. Oram and co-workers report that apo A-I and A-II interact with 
this putative HDL receptor. These receptor mediated reverse cholesterol transports 
explain why persons with higher HDL concentrations are less prone to develop 
CAD.  
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Fig. 6: Reverse Cholesterol Transport 
Another explanation for the inverse relation between HDL levels and CAD 
incidence may be related to the observation that most patients with low levels of 
HDL have elevate levels of the more cholesterol and triglyceride rich lipoproteins. 
In this case, Low HDL levels may serve only as a marker for other, concurrent 
lipid abnormalities. Just as low levels of HDL are statistically associated with 
atherosclerosis, HDL is increased on a genetic basis in familial 
hyperapolipoproteinemia. The condition has been described as being associated 
with longevity.  
Lipoprotein (A):  
Lipoprotein (a), or Lp (a), has been established as an independent CAD risk 
factor. The structure of Lp (a) is similar to that of an LDL molecule linked by a 
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disulfide bridge to apoprotein (a). It has a density of l.085gm/ml and a size of 25A 
and it migrates in the prebeta region. Lp (a) levels range from l mg/dl to 100 mg/dl, 
with the largest number of values below 20mg/dl.  
Although Lp (a) is structurally similar to LDL, the former appears to be 
regulated independently and carries an independent relation to overall coronary 
risk. If serum levels of both LDL and Lp (a) are elevated, the risk of CAD is 
markedly increased. Recent angiographic studies have documented a positive 
correlation between Lp (a) levels and the severity of coronary atherosclerosis.  
The mechanism by which high levels of Lp (a) are related to coronary 
atherosclerosis is unclear. It has been suggested that because of the structural 
similarities of Lp (a) to plasminogen, high levels of Lp (a) may inhibit the 
thrombolytic activity of naturally occurring tissue plasminogen activity. 
Plasminogen is composed of five sequences of amino acids rich in cysteine. Each 
sequence is called a kringel. Lp (a) lacks the first three kringles, but has a sequence 
that is highly homologous to the fourth kringle of plasminogen. This particular 
sequence is repeated 37 times in the Lp (a) molecule. There is no serine protease 
activity in Lp (a) and no thrombolytic activity. An alternate explanation for the 
association between elevated Lp (a) levels and atherosclerosis is that Lp (a) may 
somehow alter the LDL mediated delivery of cholesterol to the atherosclerotic 
plaque.  
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The control mechanisms of Lp (a) are unknown. Dietary changes that 
increase LDL levels do not affect Lp (a) levels. The effects of pharmacological 
agents are unclear, although Lp (a) has been reported to be decreased by niacin, 
neomycin, and stanozolol.  
Secondary Causes of Hyperlipidemia: 
LDL 
Elevated Reduced 
Hypothyroidism 
Nephrotic syndrome 
Acute intermittent porphyria 
Cholestasis 
Anorexia nervosa 
Hepatoma 
Drugs 
Thiazides, carbamazepine, cyclosporin 
Severe liver disease 
Malnutrition 
Malabsorbtion 
Gaucher’s disease 
Chronic infectious disease 
Hyperthyroidism 
Niacin toxicity 
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HDL 
Elevated Reduced 
Alcohol 
Exercise 
Estrogens 
Exposure to chlorinated hydrocarbons 
Smoking 
Type 2 DM 
Obesity 
Malnutrition 
Anabolic steroids, beta blockers 
Gaucher’s disease 
 
VLDL elevated IDL elevated 
Type 2 DM 
Obesity 
Alcohol 
Hepatitis 
Glycogen storage disorders 
Renal failure 
Sepsis 
Stress 
Cushing’s syndrome 
Hypothyroidism 
Multiple myeloma 
Monoclonal gammopathy 
Autoimmune disease 
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Pregnancy 
Acromegaly 
Lipodystrophy 
Estrogen, beta blockers, glucocorticoids, 
bile acid binding resins, retinoic acid 
 
Chylomicrons Elevated Lp(A) Elevated 
Autoimmune disease 
Type 2 DM 
Inflammation 
Renal insufficiency 
Menopause 
Orchidectomy 
Hypothyroidism 
Acromegaly 
Nephrosis 
Growth hormone, isotretinoin 
Table 5: Secondary Causes of Hyperlipidemia 
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Lipids and Atherosclerosis  
It is well established that hypercholesterolemia due to elevated blood levels 
of LDL is a major cause of CHD and that lowering elevated levels of cholesterol 
will reduce the risk of coronary disease. Inverse relationship is noted with HDL. 
There is also a weak correlation between plasma triglycerides and the incidence of 
coronary artery disease. The exact mechanism of atherogenesis is still in 
controversy. LDL particles which become oxidized (by natural process) may be 
particularly atherogenic. Receptors on the surface of macrophages within the 
plaque, binds and accumulates oxidized LDL. The formation of antibodies to 
oxidized LDL is also important in plaque formation. There is a possibility that 
chronic hyperlipidemia may initiate endothelial injury which stimulates 
atherosclerosis. This injury favours adherence of monocytes and lymphocytes at 
the focus of injury, in part owing to the stimulation of endothelial cell synthesis of 
adhesion molecules. It induces a change in the platelet membrane composition 
leading to activation and increased adhesiveness of platelets. With chronic 
hyperlipidemia, lipoproteins accumulate within the intima at sites of endothelial 
injury or dysfunction. 
A strong negative correlation has been demonstrated between plasma levels 
of HDL cholesterol and CHD. Most of the variability in HDL cholesterol levels 
70 
 
reflect HDL
2 
levels; plasma levels of the other major HDL subclass, HDL
3
, are 
fairly constant both intra and inter-individually. 
 
Fig. 7:Pathogenesis of Atherosclerosis 
 
HDL particles secreted into the circulation by liver and cholesteryl ester 
enriched macrophages are complexes of apolipoproteins and phospholipids and 
acquire unesterified cholesterol originating in cell membranes during cell renewal 
or death. Their major phospholipid is phosphatidylcholine or lecithin.  
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Both lecithin and unesterified cholesterol serve as substrates for the 
cholesterol-esterifying enzyme, lecithin cholesterol acyltransferase (LCAT), which 
circulates with HDL in the plasma. LCAT acts on the nascent HDL particles to 
generate a core of cholesteryl esters and to change the structural transition to 
mature, spherical HDL particles. LCAT also acts on mature HDL
3 
particles, i.e., 
after they have acquired cholesterol and lecithin not only from cell membranes but 
also from chylomicrons and VLDLs during those particles lipolysis. Generation of 
cholesteryl esters by the LCAT reaction leads to enlargement of the small HDL
3 
particles such that they are converted into the larger HDL
2 
particles. Formation of 
HDL
2 
increases the cholesterol-carrying capacity of HDL, and HDL cholesterol 
levels raise This drives the process termed ―reverse cholesterol transport‖, in which 
HDL returns cholesterol from peripheral tissues to the liver for excretion into the 
bile.  
The cholesteryl esters of HDL, particularly of HDL
2 
formed de novo by the 
LCAT action, need not remain within the HDL core. They can be transferred from 
HDL to the triglyceride rich lipoproteins, i.e., chylomicrons and VLDL in 
exchange for triglyceride molecules. This heteroexchange of insoluble cholesteryl 
esters and triglycerides between HDL and triglyceride rich lipoproteins is 
catalyzed by the action of cholesteryl ester transfer protein. The transferred 
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triglycerides are hydrolyzed from the HDL core by hepatic lipase, located in the 
endothelial cells of the liver. Only cholesteryl esters remain in the core those that 
were not exchanged for triglycerides. Hence HDL
2 
particles are converted back 
into the smaller HDL
3 
particles. This mechanism is the basis for the well 
established clinical observation that, individuals with permanent or temporary 
hypertriglyceridemia (due to increased levels of VLDL or due to accumulation of 
chylomicrons in the course of postprandial lipemia) have low HDL
2 
and low HDL 
cholesterol levels.  
The cholesteryl esters transferred from HDL and the triglyceride rich 
lipoproteins remain with the latter particles along their lipolytic cascades and the 
endocytotic pathways of their remnants (i.e., the LDL receptor and the scavenger 
pathways). Thus, transfer of cholesteryl esters from HDL to triglyceride rich 
lipoproteins may contribute to the atherogenic potential of chylomicrons and 
VLDL, in that ―good‖ cholesterol is turned into ―bad‖ cholesterol.  
Although there is no clinical trial directly demonstrating the benefit of 
increasing HDL cholesterol alone, Helsinki Heart Study results suggests that 
increasing HDL add benefit to lowering LDL in CHD risk reduction. Similarly, 
data from the Prospective Cardiovascular Muenster (PROCAM) Study have shown 
that the combination of LDL elevation, hypertriglyceridemia, and low HDL 
confers greater risk of CHD than elevated LDL alone. There are several causes for 
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low serum HDL cholesterol levels. Heavy cigarette smoking is a documented 
cause. Obesity is an apparent association, as is a sedentary lifestyle. 
Hypertriglyceridemia is frequently associated with very low HDL levels. Certain 
drugs can also have an appreciable depressing effect on HDL. Finally, there is 
evidence that isolated low HDL cholesterol, termed hypoalphalipoproteinemia, 
may be genetically transmitted in an autosomal dominant fashion. Patients with 
this disorder have a normal lipid profile other than the low HDL but an apparently 
increased risk for atherosclerosis.  
The recommended methods for improving HDL cholesterol values are non- 
pharmacologic; smoking cessation, weight reduction, regular and vigorous exercise 
and alteration of offending drugs, if possible. As yet, there is no direct evidence 
that drug-induced increases of low HDL cholesterol in the setting of normal LDL 
cholesterol and triglyceride levels are beneficial in CHD risk reduction. HDL 
cholesterol levels can be increased with gemfibrozil (the agent used in the Helsinki 
study) or nicotinic acid.  
The possibility that chronic hyperlipidemia, and particularly 
hypercholesterolemia, may itself initiate endothelial injury has enticed many 
investigators. Much evidence suggests that hypercholesterolemia has a variety of 
adverse effects.  
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It increases the cholesterol- phospholipid ratio of endothelial cell 
membranes, rendering them more rigid and less able to maintain their normal 
intercellular associations, potentially increasing permeability and in effect causing 
a subtle form of endothelial injury.  
It favours the adherence of monocytes and lymphocytes to the focus of 
injury, in part owing to the stimulation of endothelial cell synthesis of adhesion 
molecules.  
It induces changes in platelet membrane composition, leading to activation 
and increased adhesiveness of platelets.  
With chronic hyperlipidemia, lipoproteins accumulate within the intima at 
the site of endothelial injury or dysfunction. Although significant amounts may 
enter the arterial wall, there is some concurrent efflux, perhaps mediated by HDL.  
Most important, it provides the opportunity for oxidation of lipoproteins, yielding 
modified LDL. 
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Fig. 8: Pathogenesis of Atherogenesis 
Apoproteins: 
Apoproteins are key lipoprotein components that serve both as enzymatic 
co-factors and as recognition elements that bind to specific receptors on peripheral 
tissues, including the vascular endothelial cells. It is the apo E component of the 
chylomicron remnant, for example, that is recognized by receptors on the 
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hepatocyte. The apoproteins are distinguished alphabetically and numerically as 
apo A-I through apo E.  
A great deal of research has been conducted in the use of apoproteins as 
CAD markers. Some investigators have found that the concentration of apo A-I 
and apo B-100 are better predictors of CAD than are measurements of total plasma 
lipids or lipoproteins. In one study, apo A-I was the best predictor of 
atherosclerotic risk in patients undergoing coronary arteriography. In this study, 
higher levels of apo A-I were associated with a deceased prevalence of obstructive 
coronary lesions. Indeed, apo A-I was found to be a better CAD predictor than 
either total cholesterol or HDL.  
Apoprotein A:  
Apo A-I, the prototype of apo A, is a major protein in HDL and also is seen 
in chylomicrons. It has a molecular weight of 28,000 and is synthesized in the GI 
tract and liver. Its specific regions called amphipathic helices are enriched with 
charged amino acids that form areas of polar and non-polar residues. Apo A-I 
functions as the activator of lecithin cholesterol acyl transferase (LCAT), and also 
has been found as a degradation product in amyloid fibrils.  
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Apo A-II is a minor constituent of HDL and does not appear to be present in 
all species. Human apo A-II is of hepatic origin and consists of two identical 
chains attached by a single disulfide linkage. Apo A-II may be an activator 
triglyceride and phospholipid while utilizing HDL
2 
as its preferred substrate. Apo 
A-IV is synthesized in the gut and is present in HDL, chylomicrons and as a free 
protein. Its molecular weight is 46,000, and its structure is helical. Although its 
function is not known, it also may be an activator of LCAT.  
The genetic codes for apos A-I, A-IV and C-III are close together on the 
long arm of chromosome 11. Combined A-I/C-III deficiency is associated with 
severe premature atherosclerosis.  
Apoprotein B:  
Apo B occurs in two forms. Apo B-48 is synthesized by the small intestine, 
and apo B-100 is secreted by the liver. Apo B-48 is present on the surface of 
chylomicrons and chylomicron remnants. Apo B-100 is found in VLDL, IDL and 
LDL. Apo B-I00 is the primary apoprotein of LDL and accounts for 25 percent of 
its weight. It also is the recognition site for the LDL or apo B/E receptor on cell 
surfaces. It has recently been determined that a single gene regulates the synthesis 
of both apo B-48 and apo B-100. The gene for apo B-I00 has been localized to 
chromosome 2 and exists as a 40 kilobase structure. The structure in the amino 
acid sequence of human apo B-100 and the corresponding cDNA messenger have 
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recently been determined. A unique editing mechanism introduces a stop codon 
into the mRNA for apo B by means of a single base change. This allows the 
biosynthesis of two proteins from a single gene and mRNA, with either apo B-1 00 
or apo B-48 being synthesized.  
Apoprotein E:  
Most apo E is synthesized in the liver. However, other tissues, including the 
small bowel, kidney, adrenals, and the cells of the reticuloendothelial system, have 
the ability to synthesize this apoprotein. Apo E accounts for about 15 percent of the 
protein content of VLDL, 7 percent of the protein content of chylomicron remnants 
and 2 percent of the protein content of HDL. It can be recognized by the LDL or 
apo B/E receptor and by specific apo E receptors in the liver whose function 
appears to be the removal of chylomicron remnants. Apo E is polymorphic and 
contains three major alleles; apos E2, E3, and E4. These respective alleles are 
present in about 10 percent, 76 percent, and 13 percent of whites. Their various 
combinations result in homozygtes for apos E2/2, E4/4.  Also, apos E2/3, E2/4 and 
E3/4 exist in the heterozygous state. The polymorphism of apo E has been 
determined on a molecular basis and results from the substitution of an amino acid 
at residues 112 and 158 in the protein. About 90 percent of the patients with type 
III hyperlipoproteinema (HLP) are homozygous for the E2/2 phenotype. This 
disorder is characterized by hypercholesterolemia, hypertriglyceridemia and IDL 
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or VLDL particles abnormally enriched in cholesterol. These particles have beta 
electrophoretic mobility and are termed beta-VLDLs. Premature coronary and 
peripheral vascular disease is characteristically associated with type III HLP. Type 
III HLP is also by the delayed clearance of chylomicron remnants in the serum due 
to impaired binding of these remnants to the lipoprotein receptors in isolated cells. 
Because the E2/2 genotype occurs in 1 percent of the population, and type III HLP 
is rare, a second abnormality must be present.  
Apo E isoforms may account for as much as 15 percent of the variability of 
cholesterol and LDL levels in the population. Also, recent Finnish studies suggest 
that E4 may be associated with increased cholesterol absorption in the GI tract. In 
the Prospective Cardiovascular Muenster (PROCAM) study, E2 was associated 
with lower cholesterol levels and E3 or E4 with higher levels of total cholesterol 
and LDL, in populations with and without CAD 
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Summary of Apoproteins: 
Name Lipoprotein Function 
Apo A-I  HDL.,Chylomicrons Structural; activator of 
LCAT enzyme 
Apo A-II HDL.,Chylomicrons Structural 
Apo A-IV HDL.,Chylomicrons, 
VLDL 
Unknown 
Apo B-IOO LDL, VLDL Structural; Synthesis and 
secretions of VLDL; bind 
to LDL receptor (B/E) 
Apo B-48 Chylomicrons Structural; synthesis and 
secretions from intestine 
Apo C-I HDL.,Chylomicrons,VLDL Activator of LCAT 
Apo C-II HDL.,Chylomicrons,VLDL Activator of lipoprotein 
lipase 
Apo C-III HDL.,Chylomicrons,VLDL Stabilizes surface; 
provides negative charge 
Apo D HDL.,Chylomicrons Cholesteryl ester 
exchange 
Apo E HDL.VLDL, Chylomicrons Binds to receptor on cell 
membrane of liver (E and 
B/E) and macrophage 
Table 6: Summary of Apoproteins 
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MANAGEMENT OF HYPERLIPIDEMIA: 
Goals of Lipid Lowering Therapy: 
Elevated LDL cholesterol: Treatment of elevated LDL cholesterol can have 
either of two aims. 
Primary prevention of the complications of atherosclerosis or secondary 
treatment after complications has occurred. The rationale for primary prevention is 
based on the large body of data linking elevated levels of LDL cholesterol with 
increased CHD risk and an impressive body of clinical and experimental data 
demonstrating that reducing LDL cholesterol slows progression and may actually 
induce regression of atherosclerotic lesions. Both primary and secondary 
intervention trial indicate that total mortality can be reduced when the LDL 
Cholesterol is lowered: 
A meta-analysis of four randomized trials28, 294S, CARE, AFCAPS/ Tex 
CAPS, LIPID) 30comparing HMG – COA reductase inhibitors to control included 
30817 participants and found that HMG-COA reductase inhibitor treatment was 
associated with. 
 20% decrease in total cholesterol, and 5% increase in HDL cholesterol 
 28% decrease in LDL cholesterol, 13% decrease in triglycerides. 
 31% decrease in major coronary events and a 21% decrease in all cause 
mortality. 
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 Similar risk reduction in women and men 
 Unexpectedly the risk of stroke was also reduced by 19 to 32% by HMG-
COA reductase inhibitor treatment. 
Primary Prevention: 
The NCEP adult treatment panel III recommends measuring plasma 
cholesterol in all adults older than 20 at least every 5 yrs, with a fasting lipid panel 
i.e.TC, LDL-C, HDL-C and TG. If non-fasting lipid panel is obtained and the TG 
level is 200 mg/dl or HDL –C is less than 40 mg/dl, a follow up fasting lipid panel 
is recommended. Primary prevention goals include LDL cholesterol < 130mg/dl, 
Triglycerides <150 mg/dl and HDL cholesterol > 40 mg/dl for men and > 50 mg/dl 
for women. 
Determination of Risk: 
The patient’s risk of future events is based on presence of known CAD or 
clinical atherosclerosis in a non-coronary bed, Diabetes mellitus (CAD equivalent) 
and other risk factors. These include age (men 45 years or older and women 55 yrs 
or older), smoking, hypertension, family history of premature CAD (defined as 
CAD in first degree male relatives before age of 55 years, and in a first degree 
female relative before age of 65 yrs) and low HDL < 40 mg/dl. 
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In individuals with zero or one risk factor, life style modification alone and 
follow up testing may be used if LDL < 160mg/dl. If LDL is > 140 mg/dl, drug 
treatment is indicated. 
Ten-year risk of 10% to 20% target LDL –C for this group is less than 130 
mg/dl and these patients should be initially approached with therapeutic life style 
change (TLC). If LDL –C is more than 160 mg/dl, consideration may be given to 
starting drug therapy. 
CHD risk equivalents NCEP III recommend therapy with statins and TLCs if 
LDLC is 130 mg /dl are greater. In patients with LDL –C levels between 100 and 
130 mg/dl. TLC with are without statins. HPS trial argued that (heart protection 
study) all patients with CHD should be treated with statins and TLC regardless of 
the LDL – C level. 
Elevated Triglycerides: 
The evidence that treatment to reduce plasma triglyceride levels or increase 
levels of HDL cholesterol leads to long term heath benefits is less compelling than 
that for treatment of high LDL levels. 
Beneficial effects of niacin have been attributed, in part to its HDL raising 
effect and its action to reduce triglyceride and LDL. The management of 
hypertriglyceridemia focuses on the associated LDL and HDL concentrations as 
guidelines for therapy. Thus, the overall risk profile can be used to set goals for 
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LDL cholesterol using a low HDL level (commonly associated with 
hypertriglyceridemia) as a concomitant major risk factor for atheroscleroisis. 
However, when triglycerides levels are > 500 mg/dl, the risk of developing 
pancreatitis increase and a direct focus on lowering triglyceride is recommended 
Thus,TG levels > 500 mg/dl are generally treated with drugs where as lower levels 
(200 to 500mg/dl) are not treated unless other CHD risk factors are present. 
Treatment Modalities: 
  Therapeutic life style changes 
  Dietary modifications 
  Weight loss and exercise. 
  Pharmacological treatment 
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Major Drugs Used for the Treatment of Dyslipidemia: 
Drug Major 
indications 
Mechanism Common side effects 
HMG-COA 
reductase 
inhibitors(statins) 
Elevated LDL ↓cholesterol 
synthesis 
↓ hepatic LDL 
receptors 
↓VLDL 
production 
Myalgia, arthralgia,  
↑ transaminases, 
dyspepsia 
Bile acid 
sequestrants 
Elevated LDL ↑ bile acid 
excretion 
↑ LDL receptors 
Bloating,constipation, 
↑ TGL 
Nicotinic acid Elevated LDL, 
low HDL, 
elevated TG  
↓ VLDL hepatic 
synthesis 
Cutaneous flushing, GI 
upset, elevated glucose 
and uric acid, hepatitis 
maculopathy 
Fibric acid 
derivatives 
Elevated TG, 
Elevated 
remnants 
↑ LPL, ↓ VLDL 
synthesis 
Dyspepsia,myalgia,gall 
stones, ↑ transaminases 
Fish oils Severely 
elevated TG 
↓ chylomicron 
and VLDL 
production 
Dyspepsia, diarrhea 
Cholesterol 
absorption 
inhibitors 
Ezetimibe 
Elevated LDL ↓ intestinal 
cholesterol 
absorption 
↑ transaminases 
Table 7: Major Drugs Used for the Treatment of Dyslipidemia 
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MATERIALS AND METHODS 
 The study population includes 100 treatment naïve HIV patients, who are 
non-diabetic, non-obese and normotensive. The study was done in Government 
Rajaji Hospital, ART centre, Madurai during December 2013 to July 2014. HIV 
seropositivity was determined as per NACO guidelines.100 HIV negative age & 
sex matched controls were also included in the study. The ethics clearance was 
obtained from the Institutional ethical committee. 
Inclusion Criteria: 
 Age 20 to 40 yrs 
 Newly diagnosed HIV positive patients who are willing to participate 
in the study. 
Exclusion Criteria: 
 Diabetes 
 Hypertension 
 Obesity (BMI > 25) 
 Hypothyroidism 
 Persons who are already on lipid lowering therapy 
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A detailed clinical profile including elaborate history, general examination 
and systemic examination was done for all patients included in the study. 
Appropriate investigations were carried out. 
Blood Sampling and Laboratory Evaluation: 
 The blood samples for analysis after 12 hours of complete fasting. The 
subjects were asked to have their light, fat free diet on the day prior to sampling. 
 The Venepuncture was done in the cubital fossa. Tourniquet was used but 
was released just before sampling to avoid artifactural increase in the concentration 
of serum lipids. 
 About 10 ml of venous blood was drawn using perfectly dry and sterile 
disposable syringes. The serum was separated within 2 hours of collection to 
prevent artifactural changes in concentration of HDL and the samples were 
analyzed on the same day. 
 The lipid assay was done using the Dr.Lange LP 700 equipment. 
Dr.Lange LP 700 laboratory system:  
 The lab system LP 700 consists of following instruments: 
 LQV 018 suction device 
 LTV 015 cuvette changer (Rack) thermostat 
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 LQV 016 Universal thermostat 
 LP 700 photometer 
The filters of the wavelength 578 nm, 548 nm, 492 nm, 405 nm, 340 nm 
belong to the LP 700 and are automatically recognized by it. 
 The following standard wavelengths 800 nm, 623 nm and 520 nm are 
available additionally. 
 The cuvette compartment accepts any 10 mm square cuvette as well as the 
Dr.Lange cuvette test. 
 The minimum volumes are 
 The prefixed filling volume of Dr.Lange cuvette test. 
 450 microlitre for SM suction cuvette and 
 500 microlitre for SM square cuvette. 
The methods designed for estimation of various lipid fractions are as 
follows. 
Serum Cholesterol Estimation: 
 This was done based on CHOD-PAP method, the enzymatic calorimetric 
method. 
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Test Principle: 
 Cholesterol ester is hydrolysed by cholesterol esterase. Then free cholesterol 
is further oxidized to choles-4-En-3-one and hydrogen peroxide by the cholesterol 
oxidase. The formed hydrogen peroxide reacts with 4-amino antipyrine and phenol 
in the presence of peroxidase to produce pink coloured dye 
Serum Triglyceride Estimation: 
 Triglyceride concentration was determined by enzymatic calorimetric test as 
per details shown in the system specific working instructions supplied with kits. 
Method: 
 Enzymatic hydrolysis of triglycerides with subsequent determination of 
liberated glycerol by calorimetry. 
Test Principle: 
 Triglycerides are hydrolyzed to glycerol and free fatty acids by lipases. 
Glycerol is phosphorylated by ATP in presence of glycerol kinase to glycerol 3-
phosphate which is oxidized by the glycerol 3-phosphate oxidase releasing 
hydrogen peroxide.  Hydrogen peroxide so formed reacts with 4-
aminoantipyrine/3,5-dichloro 2-hydroxybenzene sulfuric acid to give a red color 
which is read at 510nm. 
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HDL Cholesterol Estimation: 
 This involves two steps- precipitation and cholesterol estimation of the HDL 
fraction by a modification of the method described by Burstein et al. 
Test Principle: 
 Chylomicrons, VLDL, and LDL are precipitated by adding phosphotungstic 
acid and magnesium ions to the sample. Centrifugation leaves only the HDL in the 
supernatant; their cholesterol content is determined enzymatically. 
 In patients with high triglyceride values, the HDL cholesterol estimation was 
done after dilution of serum with isotonic saline in 1:1 ratio and the resultant value 
was multiplied by 2 to obtain HDL cholesterol. This was done to prevent the 
erroneous values of HDL-cholesterol due to impaired sedimentation of precipitate 
in serum with high triglyceride concentration. 
LDL Cholesterol Estimation: 
 LDL cholesterol was calculated by using a standard WHO approved 
formula. 
LDL Cholesterol = Total Cholesterol – Triglyceride – HDL 
                                                                       5 
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Following values were taken as normal 
 Total cholesterol <200 mgs/dl 
 Triglyceride<160 mgs/dl 
 HDL-C 40-55 mgs/dl 
 LDL-C <100mgs/dl 
 VLDL-C <35mgs/dl 
 The CD4+ T lymphocyte count was estimated by fluorescence activated cell 
sorter count system (Becton Dickinson). 
 The diagnosis of dyslipidemia was made as per National Cholesterol 
Education Program Adult Treatment Panel III. 
LDL Cholesterol (mg/dl) 
<100 Optimal 
100 – 129 Near/Above optimal 
130 – 159 Borderline high 
160 – 189 High 
> 190 Very high 
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Total Cholesterol (mg/dl) 
< 200 Desirable 
200 – 239 Borderline high 
> 240 High 
HDL Cholesterol (mg/dl) 
< 40 Low 
> 60 High 
Triglycerides (mg/dl) 
< 150 Normal 
150 -199 Borderline High 
200 – 499 High 
> 500 Very High 
Table 8: NCEP ATP III Guidelines 
Outcome Measurement:  
 The results were analyzed by calculating averages, standard deviation. 
Student’s unpaired to test was applied for comparison of  study groups and P 
values were obtained. A P value of   < 0.05 was considered statistically significant. 
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Results:  
 The mean age of patients was 33±4 years and of controls was  33±5 year. 
Ratio of male to female was 75:25 in cases and 80:20 in controls. 
 
 
 
Fig. 9:  Age Distribution 
This graph shows almost equal distribution of age among both study groups . 
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Fig. 10 
    Figure 10 showed the distribution of serum triglycerides (mg/dl) in both study 
groups and the mean values are 174±75 in cases and 133±35 in controls. 
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Fig. 12 
Figure 12   showed the distribution of serum LDL-C (mg/dl) in both study groups 
and the mean values are 114±28 in cases and 84±9 in controls. 
 
Fig. 13 
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Fig. 14 
Figure 14 showed the distribution of serum total cholesterol (mg/dl) in both study 
groups and the mean values are 167±11 in cases and 183±8 in controls. 
 
Fig. 15 
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Fig. 16 
Figure 16 showed the distribution of serum HDL-C (mg/dl) in both study groups 
and the mean values are 47±6 in cases and 49±3 in controls. 
 
Fig. 17 
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Fig. 18 
Figure 18 showed the distribution of serum VLDL-C (mg/dl) in both study groups 
and the mean values are 32±6  in cases and 31±6  in controls. 
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Fig. 20 
Group 1- cases with dyslipidemia. Group 2- cases without dyslipidemia 
 
Fig. 21 
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LIPID PROFILE OF CASES AND CONTROLS: 
Parameter(mg/dl) Cases Controls P value 
Triglycerides 174±75 133±35 <0.001 
Total cholesterol 167±11 183±8 <0.001 
LDL-C 114±28 84±9 <0.001 
HDL-C 47±6 49±3 0.0027 
VLDL-C 32±6 31±6 0.22 
 
Note: All values are in mean ± standard deviation 
Table 9: Lipid Profile of Cases and Controls 
HIV patients with dyslipidemia has significantly lower CD4+ count (mean 
153±23) when compared to patients with normal lipid profile (mean 270±43). 
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DISCUSSION 
 In this study, including 100 HIV positive cases and 100 HIV negative 
controls we observed a significant increase in triglycerides, LDL-C  and significant 
decrease in total cholesterol and HDL-C levels. 
 HIV infection causes a specific pattern of derangement in lipid profile, 
resulting from a combination of increased production and decreased clearance of 
lipoproteins. 
 It has been found that out of 18 differentially expressed proteins in HIV 
infected cells, six kinases/enzymes are expressed exclusively in HIV infected cells. 
They are (CO3, P3C2B, FAS, GPX1, ACSL1, and KPCB), also there is slight 
downregulation of one isomerase PDIA3 after chronic HIV infection. 
 HIV infection alone without any influence of human genetic factors or of 
antiretroviral drugs induces these novel cellular proteins and enzymes. These 
further increase the quantity of  LDL, secrete TGs, enhance fatty acid synthesis, 
alter the lipid transport, metabolism and oxidize lipids. 
 The main target of HIV infection is CD4+ T lymphocyte because of affinity 
of the virus toward the CD4+ surface marker. There is a gradual decline in CD4+ T 
lymphocyte levels resulting in increased risk for development of opportunistic 
infections. 
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 Secondary acute infectious disease has been more associated with lipid 
abnormalities, which causes dyslipidemia independent of infectious agent and are 
brought about by various cytokines regulating the immune response to infection.  
 Hypertriglyceridemia was the first reported dyslipidemia in HIV infected 
patients. Hypo HDL- cholesterolemia, Hyper LDL- cholesterolemia and 
hypocholesterolmia has also been reported. 
 The hypertriglyceridemia correlates with opportunistic infections and to 
interferon-α.  Interferon-α increases triglycerides by two mechanisms 
1. Decrease in TGL clearance. 
2. Increase in de novo hepatic lipogenesis and VLDL production. 
This hepatic lipogenesis is stimulated by three cytokines. 
1. Tissue necrotic factor- alpha(TNF-α) 
2. Interleukin 1 and 6(IL-1 & IL-6) 
3. Interferon-alpha(IFN-α) 
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Acute infections may increase TGL by the way of steroids or cytokines other 
than interferon-α or TNF-α. TNF-α is also found to play a role in per oxidation of 
plasma lipoproteins and lipids by stimulating the production of reactive oxygen 
species. Lipid per oxidation explains the alterations in cholesterol metabolism and 
these changes have significant effect in immune dysfunction in HIV patients. 
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CONCLUSION 
 From the above findings, it is apparent that HIV infection induces changes in 
lipid profile, which should be measured to determine the high risk patients of 
myocardial infection before enrollment of HAART. 
 All HIV infected persons should have their fasting lipid profile done before 
starting HAART with periodic repetitions thereafter since significant 
increases in plasma triglycerides and total cholesterol levels, are often 
associated with lipodystrophy and impaired glucose tolerance are seen in 
HIV patients on HAART. 
 Therefore lipid profile serves as a good index for disease progression, 
intervention and management of HIV patients.  
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ABBREVIATIONS 
HIV Human immunodeficiency virus 
AIDS Acquired immunodeficiency virus 
WHO World health organization 
HAART Highly active antiretroviral therapy 
ART Anti retroviral therapy 
TGL Triglyceride 
LDL Low density lipoprotein 
HDL High density lipoprotein 
VLDL Very low density lipoprotein 
TC Total cholesterol  
Lp-a Lipoprotein a 
NCEP ATP National cholesterol education 
programme adult treatment panel 
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PROFORMA 
 
Name:                       Age / Sex:               Occupation: 
Presenting complaints: 
  
 
Past History: 
H/o DM, HT, drug intake, CAD, Thyroid disorders  
Clinical Examination: 
General Examination: 
  Consciousness, Pallor, jaundice, Clubbing, Lymphadenopathy,  
Vitals:  
PR, BP, RR, SpO2. 
Systemic examination: 
 CVS: RS: ABDOMEN: CNS: 
Laboratory investigations: 
                Lipid profile, FBS, PPBS, TSH  
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 MASTER CHART - CASES 
S.NO AGE SEX TGL T.C LDL HDL VLDL CD4 
1 34 M 132 169 89 49 20 289 
2 31 M 124 178 101 43 31 305 
3 28 M 120 161 127 54 37 186 
4 39 F 267 157 121 49 28 257 
5 27 M 273 186 129 46 37 289 
6 35 M 126 169 128 51 40 306 
7 33 M 117 167 110 45 34 309 
8 36 M 294 164 165 54 23 132 
9 38 M 132 178 105 38 33 189 
10 21 F 253 168 117 48 41 291 
11 32 F 275 156 119 44 34 144 
12 30 M 240 148 110 49 28 378 
13 24 M 110 169 179 53 20 156 
14 33 M 98 149 89 48 27 345 
15 35 M 283 147 97 55 31 179 
16 21 M 116 170 103 47 37 239 
17 28 F 129 178 110 32 29 167 
18 29 M 139 143 121 50 36 149 
19 31 M 98 162 85 53 34 267 
20 34 F 128 171 168 48 32 158 
21 38 M 292 156 173 51 38 135 
22 32 M 131 177 94 43 39 231 
23 37 F 127 178 119 33 29 167 
24 28 M 179 173 121 49 37 129 
25 31 M 343 164 87 53 31 245 
26 36 F 122 179 76 47 36 276 
27 29 M 281 172 105 49 37 150 
28 37 F 129 166 114 54 42 209 
29 36 F 119 162 120 52 32 214 
30 31 M 277 160 83 50 39 119 
31 34 M 134 171 161 54 30 141 
32 29 M 259 169 114 34 35 153 
33 22 M 121 163 109 47 37 219 
34 39 M 110 174 98 49 32 137 
35 40 M 99 172 79 50 27 171 
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36 23 F 114 161 106 51 23 236 
37 35 F 285 170 110 49 27 163 
38 39 M 135 177 124 54 29 304 
39 32 F 280 165 166 53 30 128 
40 27 F 125 167 120 39 32 172 
41 35 M 130 174 119 51 19 219 
42 39 M 131 175 113 47 36 278 
43 26 M 127 179 169 43 34 178 
44 21 M 239 178 71 46 36 304 
45 29 M 295 171 84 44 38 133 
46 38 M 234 170 93 48 34 289 
47 25 F 129 174 90 31 29 184 
48 39 M 110 178 91 49 26 257 
49 22 M 103 174 99 53 20 117 
50 32 M 117 179 84 50 14 271 
51 38 M 131 179 118 49 34 231 
52 31 M 114 170 79 48 33 327 
53 35 M 278 176 127 54 37 132 
54 34 M 131 178 106 55 39 287 
55 38 F 126 179 89 46 36 219 
56 32 F 284 175 94 43 35 148 
57 36 M 131 179 110 49 39 245 
58 31 M 110 174 108 35 20 149 
59 37 M 119 179 112 49 29 267 
60 35 M 121 176 172 47 26 156 
61 29 M 132 170 129 45 31 215 
62 34 M 290 179 88 54 32 179 
63 39 M 123 179 79 53 26 259 
64 37 F 131 170 80 33 27 198 
65 32 M 125 176 84 55 30 233 
66 39 M 119 141 123 47 32 139 
67 36 M 127 178 113 44 31 264 
68 35 M 298 147 119 43 35 182 
69 39 M 135 179 123 42 37 235 
70 28 M 131 148 186 48 39 110 
71 35 F 276 140 100 49 37 139 
72 31 M 244 149 98 36 32 176 
73 38 M 139 148 91 43 39 219 
74 34 M 282 147 87 54 30 169 
120 
 
75 39 M 128 174 84 55 38 251 
76 34 F 240 170 99 51 29 345 
77 39 M 372 179 115 43 35 129 
78 35 M 112 159 126 54 25 367 
79 31 M 130 148 118 52 37 310 
80 39 F 89 179 179 49 30 176 
81 34 F 291 171 120 47 33 159 
82 36 M 117 151 123 34 36 190 
83 32 M 131 178 107 48 23 312 
84 23 M 139 172 103 47 31 116 
85 29 M 243 175 188 47 36 176 
86 34 M 127 179 101 49 30 346 
87 38 F 286 164 174 44 32 109 
88 34 M 134 168 119 54 36 218 
89 39 M 125 161 116 40 30 152 
90 36 F 129 146 92 50 31 232 
91 27 M 279 149 90 51 47 112 
92 33 F 98 146 87 53 29 237 
93 37 M 297 170 108 52 35 138 
94 39 M 103 165 119 48 36 243 
95 38 M 112 160 116 46 33 159 
96 35 M 135 149 129 49 32 274 
97 32 F 127 178 120 33 38 125 
98 31 M 134 174 191 50 30 160 
99 30 M 258 171 110 53 34 164 
100 34 M 222 169 99 37 39 181 
 
 
 
 
 
121 
 
MASTER CHART - CONTROLS 
S.NO AGE SEX TGL T.C LDL HDL VLDL 
1 35 M 134 165 76 46 40 
2 30 M 132 172 73 49 34 
3 30 M 138 170 72 52 23 
4 39 M 129 164 80 51 33 
5 26 M 134 183 85 49 41 
6 36 M 231 190 87 46 34 
7 32 M 139 184 89 54 28 
8 37 M 129 180 85 48 20 
9 39 M 132 163 76 52 27 
10 20 F 138 167 78 47 31 
11 33 F 132 177 95 49 37 
12 29 M 134 174 95 46 29 
13 25 M 132 161 86 50 36 
14 34 M 117 180 76 52 34 
15 36 M 134 185 73 48 32 
16 20 M 140 162 99 46 32 
17 27 F 128 171 97 51 27 
18 30 M 92 174 87 49 23 
19 32 M 104 169 66 46 27 
20 35 F 249 170 67 55 29 
21 37 M 116 170 69 52 30 
22 33 M 86 168 70 46 32 
23 36 M 95 167 72 49 19 
24 29 M 108 186 77 51 36 
25 30 M 112 180 78 49 34 
26 37 F 234 174 83 46 36 
27 28 M 96 172 87 54 38 
28 36 F 88 188 89 52 34 
29 37 F 95 188 94 42 29 
30 30 M 101 172 97 46 26 
31 35 M 86 174 84 45 20 
32 28 M 98 172 87 53 20 
33 23 M 92 180 78 46 29 
34 40 M 246 163 95 52 26 
35 39 M 94 161 94 50 31 
122 
 
36 24 F 124 174 97 55 32 
37 36 F 133 175 99 46 26 
38 38 M 130 167 73 49 27 
39 33 F 141 190 76 51 30 
40 26 F 148 162 84 47 32 
41 34 M 121 168 94 54 31 
42 40 M 129 174 97 46 35 
43 27 M 126 167 85 48 37 
44 23 M 144 188 80 53 39 
45 28 M 129 190 72 54 37 
46 35 M 124 184 76 45 32 
47 27 M 139 163 89 49 39 
48 38 M 239 175 87 53 30 
49 23 F 106 162 76 46 25 
50 34 M 112 185 78 48 37 
51 37 M 109 163 72 51 30 
52 30 M 117 177 71 47 33 
53 36 M 148 160 91 49 36 
54 33 M 138 168 93 52 23 
55 39 F 124 179 95 47 31 
56 31 F 131 165 94 54 36 
57 37 M 103 189 84 46 30 
58 30 M 139 166 78 49 32 
59 38 M 140 182 97 51 36 
60 36 M 142 168 99 54 30 
61 28 M 135 172 92 47 31 
62 35 M 123 184 81 49 47 
63 40 M 241 162 83 51 29 
64 38 M 137 166 77 53 35 
65 31 M 138 176 75 46 36 
66 38 M 134 174 86 48 33 
67 37 F 135 188 89 50 32 
68 34 M 134 164 95 54 38 
69 40 M 132 178 97 49 30 
70 27 M 131 182 99 53 34 
71 36 F 230 180 76 55 26 
72 30 M 146 162 71 45 20 
73 39 M 133 164 73 49 14 
74 33 M 138 168 75 46 34 
123 
 
75 38 M 131 170 77 51 33 
76 35 M 136 180 81 49 37 
77 37 M 125 172 89 53 39 
78 34 M 139 182 91 48 36 
79 32 M 139 169 76 51 35 
80 38 F 148 174 79 54 39 
81 35 F 141 183 77 47 20 
82 37 M 104 176 99 53 29 
83 32 M 137 167 97 49 26 
84 24 M 139 184 93 51 31 
85 30 M 138 163 91 50 32 
86 34 M 134 175 82 45 26 
87 38 M 132 169 86 54 27 
88 35 M 139 178 75 46 30 
89 39 M 233 183 82 51 32 
90 36 F 118 177 91 50 31 
91 28 M 122 160 93 46 35 
92 33 F 101 165 97 49 37 
93 39 M 132 176 77 51 39 
94 39 M 104 186 81 43 37 
95 38 M 92 167 92 50 32 
96 35 M 109 183 99 47 23 
97 32 M 103 164 82 49 37 
98 31 M 103 170 88 53 29 
99 30 M 136 162 76 46 39 
100 34 M 102 167 80 44 21 
 
